{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"9f7abff5-de87-4959-b080-10eac9863ba7","name":"Research Synthesis: Carnosine Anti-Glycation — full paper","doi":"10.17605/OSF.IO/5N3MV","doi_status":"minted","osf_url":"https://osf.io/5n3mv/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_3233e9a2f9ee463f/chain","content_hash":"sha256:562d61ca23394d7b4f4255978454c70e5553604a3292466ec9cb7da2cd933e9f","provenance_passport":{"publication_id":"9f7abff5-de87-4959-b080-10eac9863ba7","submission_id":"ef42bd37-05c1-44fb-b0ef-4156c97e09fa","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:562d61ca23394d7b4f4255978454c70e5553604a3292466ec9cb7da2cd933e9f","persistent_identifiers":{"doi":"10.17605/OSF.IO/5N3MV","osf_url":"https://osf.io/5n3mv/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":null,"provenance":{"dw_artifact_id":"claim_3233e9a2f9ee463f","dw_chain_url":"https://provenance.researka.org/artifacts/claim_3233e9a2f9ee463f/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"9f7abff5-de87-4959-b080-10eac9863ba7","object_type":"publication","parent_object_id":"ef42bd37-05c1-44fb-b0ef-4156c97e09fa","title":"Research Synthesis: Carnosine Anti-Glycation — full paper","body_markdown":"## Research Synthesis: Carnosine Anti-Glycation — full paper\n\n### Abstract\n\nThis paper synthesizes carnosine anti glycation as an aging-related intervention across 38 included source papers and 1568 high-confidence extracted claims.\n\nThe evidence profile contains 2 direct clinical sources, 26 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 205 cross-study disagreements across the evidence base.\n\nPositive study-level signals concentrate in the frailty, safety and comorbidity and immune and inflammation outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes, and negative signals in the contextual adjacent evidence and cardiometabolic outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.\n\nThe conclusion is that carnosine anti glycation remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim.\n\nThis conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.\n\n### Introduction\n\nThe global burden of age-related chronic disease — spanning cardiometabolic disorders, cognitive decline, and functional disability — has intensified the search for interventions that target fundamental aging biology rather than individual organ systems. Geroscience posits that hallmarks such as protein crosslinking, oxidative stress, and chronic low-grade inflammation represent shared upstream drivers of multiple disease trajectories, and that modulating these pathways could compress morbidity in later life. Among candidate molecules, Carnosine anti glycation has drawn attention as a naturally occurring dipeptide with putative anti-glycation, antioxidant, and metal-chelating properties. Yet the question of whether Carnosine anti glycation supplementation can meaningfully alter healthspan or lifespan trajectories in humans remains unresolved. Evidence suggests that even well-studied aging biomarkers such as gait speed — where thresholds of 0.8 m/s (Studenski 2011) and 0.6 m/s (Cesari 2009) delineate mobility risk strata — show annual declines on the order of 0.05 m/s (Bohannon 1997), underscoring the incremental nature of functional deterioration and the challenge of detecting intervention effects over realistic trial durations.\n\nThe geroscience hypothesis reframes drug development by proposing that interventions targeting aging biology — rather than single disease endpoints — could yield multiplicative benefits across organ systems. In this framework, Carnosine anti glycation is of particular interest because its proposed mechanism of action — scavenging reactive carbonyl species to prevent advanced glycation end-product (AGE) formation — intersects with a pathway implicated in vascular stiffening, renal decline, neuropathy, and cartilage degradation. The logic of repurposing Carnosine anti glycation as an anti-aging agent rests on these observational associations and its favorable safety profile as a dietary supplement. However, whether intervening on the glycation pathway — as opposed to merely observing its correlates — can reverse or slow these trajectories is a fundamentally different empirical question.\n\nSeveral unresolved questions constrain the translational potential of Carnosine anti glycation. First, the duration of most trials — typically under 12 weeks — may be insufficient to detect effects on endpoints such as vascular stiffness, renal function, or cognitive trajectories that unfold over years or decades. Second, population specificity poses a challenge: carnosine supplementation showed benefits in younger cognitive cohorts (OToole 2025) but not uniformly across age groups, and the relevance of AGE-reduction strategies may differ between diabetic and non-diabetic populations. Third, the tension between positive findings in immune-inflammation outcomes (Sukon 2024) and null mechanistic signals (Lee 2026) illustrates the broader difficulty of translating cell-level anti-glycation effects to clinical inflammation endpoints. Whether Carnosine anti glycation can deliver meaningful benefit in aging populations will require trials that extend beyond surrogate markers (Ioannidis 2005) to functional and hard clinical endpoints.\n\nThis synthesis addresses these gaps by systematically mapping the evidence for Carnosine anti glycation across outcome classes, distinguishing clinical from mechanistic findings, and explicitly weighting the tensions that pervade the literature. Across 38 curated reference papers, positive signals appear in frailty and safety-comorbidity domains, while negative or null findings dominate cardiometabolic and contextual-outcome classes, with cross-study disagreements identified across outcome pairings. The structured approach separates the question of mechanistic plausibility — which appears well-supported by in-vitro and observational data — from clinical efficacy, which remains uncertain and context-dependent. By organizing evidence according to outcome class, directness, and effect direction, rather than presenting an exhaustive inventory of individual studies, this synthesis aims to clarify where Carnosine anti glycation evidence converges, where it diverges, and what specific gaps future trials must address. The central question — whether Carnosine anti glycation represents a viable anti-aging intervention — cannot be answered by any single study; it requires the kind of cross-domain integration attempted here, bounded by the recognition that the mechanistic-to-clinical translation remains incomplete.\n\n### Background\n\nThe background evidence for carnosine anti glycation is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Movahedian 2025, Ozdemir 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.\n\nThe direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.\n\nAcross the retained sources, positive signals cluster around the frailty, safety and comorbidity and immune and inflammation outcome classes; null signals around the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes; and negative or adverse signals around the contextual adjacent evidence and cardiometabolic outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.\n\nThe study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.\n\nThe resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct clinical signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.\n\nNo section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.\n\nThis distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.\n\nThe clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.\n\n### Methods\n\n#### Review type and protocol\nThis manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-carnosine_anti_glycation-v06-DAILY-2026-05-31T07-31-55Z-R2`.\n\n#### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-05-31.\n\n#### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `carnosine anti glycation AND aging AND human`\n- `carnosine anti glycation AND older adults`\n- `carnosine anti glycation AND randomized controlled trial`\n- `carnosine AND aging AND human`\n- `carnosine AND older adults`\n- `carnosine AND randomized controlled trial`\n- `anti-glycation AND aging AND human`\n- `anti-glycation AND older adults`\n- `anti-glycation AND randomized controlled trial`\n- `AGEs AND aging AND human`\n\n#### Eligibility criteria\n- Sources whose primary content addresses carnosine anti glycation.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n#### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 171 records in the receipt-candidate union, 51 were classified as source candidates and 38 were admitted as traceable synthesis sources. No additional records were excluded after final source admission.\n\n#### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 171 |\n| Classified source candidates | 51 |\n| No extractable claims | 35 |\n| None-only claim binding | 11 |\n| Partial/none-only claim binding | 51 |\n| Partial-only candidates | 17 |\n| Strict high-confidence sources | 6 |\n| Admitted final sources | 38 |\n\n#### Exclusion reasons\n- Non-traceable findings (claim could not be linked to source text): 0 records.\n- Wrong population / off-topic sources excluded at screening.\n- Duplicate records deduplicated by DOI / PMID before screening.\n\n#### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Source verification in the public bundle is limited to reference-level metadata; reported statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.\n\n#### Risk-of-bias appraisal\nPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.\n\n#### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, cognitive, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, frailty, immune, immune and inflammation, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n#### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n#### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. This run is certified under the `researka_agent_certified` accountability model — trust is machine-verifiable rather than dependent on author signoff.\n\n### Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.\n\n| Outcome class | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Contextual Adjacent Evidence | n=20; claims=657 | null signal in 15/20 sources | 16 indirect; 4 review | limited corpus depth in this outcome class |\n| Cardiometabolic | n=6; claims=513 | null signal in 4/6 sources | 2 direct; 2 indirect; 2 review | limited corpus depth in this outcome class |\n| Deficiency Prevalence | n=3; claims=178 | null signal in 3/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class |\n| Immune and Inflammation | n=2; claims=22 | positive signal in 1/2 sources | 2 indirect | limited corpus depth in this outcome class |\n| Cognitive | n=1; claims=48 | null signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n| Dosing and Pharmacokinetics | n=1; claims=7 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Frailty | n=1; claims=34 | positive signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Immune | n=1; claims=35 | null signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n| Mortality and Survival | n=1; claims=12 | unclear signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |\n| Muscle Function | n=1; claims=37 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n| Safety and Comorbidity | n=1; claims=25 | positive signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n\n#### Cardiometabolic Outcomes\n\nThe synthesis examined six studies addressing carnosine and advanced glycation end-products (AGEs) in cardiometabolic contexts.\n\nQuantitative findings across these studies present a mixed profile. Ozdemir 2025 found metabolic and hormonal improvements in the low-AGE diet group, with several endpoints reaching significance (P = 0.027, P = 0.001).\n\nMechanistically, carnosine's anti-glycation properties may attenuate AGE accumulation and downstream oxidative stress pathways relevant to cardiometabolic health. The clinical RCT by Movahedian 2025 provides direct evidence that AGE modulation via melatonin affects inflammation and oxidative stress markers. Ozdemir 2025's RCT data suggest that reducing dietary AGE intake can improve metabolic and hormonal profiles in PCOS patients. Observational data from Xue 2025 and Nevarez 2025 provide cross-sectional associations but cannot establish causality regarding AGE-mediated cardiometabolic pathways.\n\nWithin-corpus tensions emerge between studies reporting null or non-significant findings and those demonstrating significant cardiometabolic benefits. Ozdemir 2025 demonstrated significant metabolic improvements (P = 0.001) that contrast with the null findings from observational studies. These disagreements suggest that carnosine's cardiometabolic effects are context-dependent, with intervention type, population, and endpoint specificity moderating the observed effects.\n\n#### Cognitive Outcomes\n\nThe corpus contains a single direct evidence source addressing cognitive outcomes in the context of anti-glycation interventions: a systematic umbrella review and meta-meta-analysis by Singh 2025. This review synthesized evidence across multiple domains, reporting that shorter intervention durations of 1 to 3 months and exergames (video games requiring physical movement) showed the largest effects on general cognition and memory. The study design was observational and review-level, with no enrolled clinical population specific to carnosine supplementation (Singh 2025).\n\nThis pattern of mixed significance underscores the context-dependent nature of cognitive outcomes: short-duration interventions and active gaming modalities appear efficacious, whereas other exercise forms or durations may not reach significance. The evidence does not directly evaluate carnosine's anti-glycation mechanisms in cognitive domains.\n\nMechanistically, the anti-glycation properties of carnosine may relate to cognitive outcomes through protection against advanced glycation end-product (AGE) accumulation in neural tissue, a pathway implicated in neurodegeneration. However, the sole available review (Singh 2025) does not address this mechanistic pathway directly; instead, it evaluates physical activity and exergaming interventions that may share downstream neuroprotective effects such as enhanced cerebral blood flow and neurotrophic factor expression. Preclinical data from the broader carnosine literature suggest glycation-inhibiting properties relevant to brain aging, but this mechanistic substrate is not yet grounded in human-RCT evidence specific to carnosine supplementation for cognition.\n\nWithin the corpus, a notable tension exists: the cognitive outcome class is populated solely by Singh 2025, which addresses exercise rather than carnosine directly, creating an indirect evidence gap. This heterogeneity parallels the broader thesis that the carnosine anti-aging case remains incomplete: mechanistic plausibility for anti-glycation benefits in cognition coexists with sparse or absent direct human-RCT evidence for carnosine supplementation. The boundary conditions for any cognitive benefit remain to be established through targeted interventional trials.\n\n#### Contextual Adjacent Evidence Outcomes\n\nThe evidence base for advanced glycation end products (AGEs) as contextual biomarkers is derived entirely from observational cohort designs, with no interventional RCTs directly testing carnosine's anti-glycation effects within this corpus. Studies span diverse clinical populations including children, adults with type 2 diabetes, patients with aortic stenosis, exfoliation glaucoma, hypertrophic cardiomyopathy, endometriosis, and diabetic retinopathy. The indirectness of this evidence to carnosine itself is substantial, as most studies measured circulating or tissue AGE levels rather than investigating carnosine supplementation.\n\nQuantitative findings across these cohorts consistently demonstrate that AGE levels are significantly elevated in disease states relative to controls. Selcuki 2026 demonstrated significantly elevated AGEs in endometriosis patients compared with controls (P < 0.001).\n\nMechanistically, AGE accumulation is proposed to contribute to tissue damage through cross-linking of structural proteins, activation of the receptor for AGEs (RAGE), and downstream NF-κB signaling. Nowotny 2015 outlined that the proteasomal system degrades more than 90% of oxidatively damaged proteins, a pathway potentially overwhelmed by AGE-modified substrates in diabetes. Chuntakaruk 2021 provided preclinical data showing that purple corn anthocyanins suppressed NF-κB and MAPK signaling in AGE-induced porcine cartilage degradation, suggesting a mechanistic avenue for anti-glycation interventions. Zhang 2025 reported that three months of intervention with Vaccinium myrtillus extract (600 mg/day) reduced CML levels, though CEL levels were not significantly changed. This mechanistic substrate underscores biological plausibility but does not directly address carnosine's efficacy.\n\nMechanistically, the null findings across these disparate clinical contexts—frailty, PCOS, and valve prolapse—suggest that glycation-related deficiency prevalence is not a primary driver of pathology in these conditions. These observational data provide indirect evidence that does not support a strong, uniform prevalence signal.\n\nA minor tension within this outcome class is the variation in reported p-values. This pattern of mixed non-significance underscores the bounded, context-dependent nature of the evidence, where no single glycation-related deficiency emerges as a consistently prevalent biomarker across these studied conditions.\n\n#### Dosing and Pharmacokinetics Outcomes\n\nIn a clinical observational cohort, the NEAT trial investigated carnosine supplementation in adults, examining cognitive performance metrics as a primary endpoint. The study design involved administration of carnosine with the primary focus on evaluating speed, accuracy, and efficiency as key cognitive outcomes. This trial provides foundational data on the pharmacokinetic and dose-response relationship of carnosine in human participants, establishing a framework for understanding its functional effects in a controlled setting.\n\nQuantitative analysis from the observational cohort revealed a significant age-dependent response to carnosine supplementation. Specifically, scores for speed, accuracy, and efficiency were significantly higher for individuals aged 23-35 years than those in the older age groups, as illustrated in the study's figures. However, in the unadjusted model, the overall effect of supplementation did not reach statistical significance, indicating a context-dependent profile where benefits are concentrated in a younger demographic.\n\nMechanistically, the observed age-related divergence in cognitive outcomes may reflect differential bioavailability or cellular uptake of carnosine across the lifespan, a hypothesis supported by its role as a dipeptide with complex metabolism. Preclinical data suggest that carnosine's anti-glycation properties are modulated by tissue-specific carnosinase activity, which could vary with age. This mechanistic substrate provides a plausible explanation for the functional finding of enhanced efficacy in younger participants.\n\nWithin the corpus, the evidence for carnosine's dosing and pharmacokinetic profile presents a nuanced picture. The NEAT trial's findings of null overall unadjusted effects but significant benefits in a specific subgroup highlight a tension between generalized supplementation expectations and age-specific efficacy. This context-dependent outcome underscores that the boundary conditions for carnosine's cognitive benefits remain to be fully established, reinforcing the incomplete nature of the current evidence base.\n\nMechanistically, the association between elevated advanced glycation end products and mobility decline aligns with the proposed anti-glycation role of carnosine. Higher skin autofluorescence reflects cumulative glycation damage in structural proteins, a process that carnosine may attenuate through its nucleophilic carbonyl-scavenging properties. The functional endpoints measured—gait speed and sit-to-stand performance—directly reflect muscle and connective tissue integrity, which are vulnerable to glycation-mediated cross-linking. This observational evidence provides a plausible mechanistic bridge between carnosine's biochemical activities and clinically relevant frailty outcomes.\n\n#### Immune and Inflammation Outcomes\n\nThe available evidence on carnosine's anti-glycation effects in the context of immune-inflammatory outcomes is derived exclusively from observational studies. Sukon 2024 conducted an observational cohort in adults with active immune-mediated ocular inflammatory diseases, assessing the association between skin autofluorescence (SAF) advanced glycation end product (AGE) levels and disease activity. Lee 2026 explored the anti-inflammatory potential of Aloe vera flower components in a skin inflammation model induced by glyoxal-derived AGEs (GO-AGEs). The directness of evidence from these studies is classified as indirect, as they do not evaluate exogenous carnosine supplementation directly but rather examine the broader relationship between AGE burden and inflammatory processes.\n\nThis finding suggests that lower glycation burden, as measured by SAF, correlates with a state of active inflammatory disease in this specific population. The study reported two p-values of P = 0.04 from its multivariate analysis. In contrast, the experimental work by Lee 2026, which investigated the mitigation of GO-AGE-induced skin inflammation by Aloe vera compounds, reported null findings for its primary endpoints, indicating no significant anti-inflammatory effect in that model. These exact p-values are detailed in the per-study evidence table.\n\nMechanistically, the hypothesis linking carnosine's anti-glycation properties to immune modulation posits that reducing AGE accumulation may attenuate the receptor for AGE (RAGE) signaling pathway, a key driver of sterile inflammation. The finding from Sukon 2024 (P = 0.04) provides indirect human observational support for the concept that AGE levels are dynamically associated with inflammatory disease activity. Preclinical data from Lee 2026 tested whether blocking AGE formation or action could reduce inflammation in a glyoxal-AGE skin model. The integration of these studies suggests that while the AGE-inflammatory axis is clinically relevant, the specific intervention point—whether via prevention (anti-glycation) or mitigation—is critical.\n\nA notable within-corpus tension exists regarding the direction of the association between AGE levels and inflammation. By contrast, Lee 2026's null results in an induced AGE-inflammation model suggest that simply administering an anti-glycation agent did not reverse the inflammatory cascade. This disagreement highlights the complexity of the AGE-immune interaction and underscores that the relationship is likely context-dependent, varying with disease state, tissue, and timing of measurement.\n\nThe quantitative findings for the mortality and survival outcome class are characterized by null or near-null effects. This result points to a lack of a meaningful protective or harmful association between dAGEs consumption and the studied survival endpoint. The review, as a synthesis of observational data, provides effect estimates that are not derived from controlled interventions but from population-level associations, which are subject to confounding. Therefore, the observed HR of 0.99 should be interpreted within the context of methodological limitations inherent to observational cohort designs.\n\nMechanistically, the rationale for a survival benefit from reducing glycative stress via carnosine involves its known capacity to inhibit AGE formation and accumulate in long-lived tissues. However, the clinical evidence from this observational review does not translate this mechanistic plausibility into a clear mortality benefit. This disconnect highlights a common challenge in nutritional epidemiology, where biological activity demonstrated in preclinical or in vitro models does not consistently manifest as a significant effect in human observational studies. The review by Pascual-Morena (2025) thus underscores that the anti-glycation action of carnosine, while biochemically relevant, may not be a dominant determinant of cancer or overall survival at the dietary exposure levels studied.\n\nQuantitative findings from this observational work revealed multiple statistically significant associations between glycation markers and biomechanical properties. These statistically significant relationships suggest a plausible mechanistic link between glycation processes and tissue biomechanics, though the cross-sectional design precludes causal inference.\n\nMechanistically, the observation that AGE levels correlate with corneal biomechanical properties aligns with established pathways whereby glycation cross-links alter tissue stiffness and elasticity. This human observational data provides a clinical correlate to preclinical evidence suggesting carnosine may inhibit AGE formation. However, the study did not measure muscle tissue directly, and the translation from corneal biomechanics to skeletal muscle function requires caution. The pathway from glycation inhibition to functional improvement remains theoretically plausible but empirically unvalidated in this specific context.\n\nQuantitative findings from this cohort showed statistically significant improvements in the intervention arm. These results suggest a favorable modulation of surrogate markers in CCS patients, supporting a potential anti-glycation benefit in the context of existing cardiovascular disease.\n\n#### Deficiency Prevalence Outcomes\n\nWithin the corpus, substantial tensions exist regarding the consistency of AGE biomarker associations. Dahlen 2025 examined healthy elderly (HE) and frail elderly (FE) populations, assessing frailty and comorbidity status. Melamed 2025 conducted a systematic review and meta-analysis on mitral valve prolapse prevalence in general and hospital cohorts.\n\nQuantitative findings from these cohorts consistently report null or non-significant associations for glycation-related deficiency prevalence. The exact p-values from Dahlen 2025's frailty analysis are available in Table 2.\n\nDeficiency Prevalence is retained as a separate Results slice (n=3; null signal in 3/3 sources; 2 indirect; no direct clinical anchor) and is not pooled into adjacent endpoint classes.\n\n#### Frailty Outcomes\n\n**Frailty Outcomes.**\nThe observational cohort study by Park 2025 examined the relationship between advanced glycation end products, measured via skin autofluorescence, and mobility decline in a population of adults. The analysis structured participants into quartile groups based on skin autofluorescence values to compare physical function outcomes. Key endpoints included sit-to-stand test performance and gait speed, which are established mobility measures relevant to frailty assessment. The study reported highly significant associations across multiple comparisons, with p-values consistently below 0.001 for the primary functional measures.\n\nQuantitative findings from Park 2025 demonstrate that the highest quartile (Q4) of skin autofluorescence exhibited a general decline in sit-to-stand performance and gait speed compared to lower quartiles. These effect sizes suggest a dose-response relationship between glycation burden and functional impairment. The consistency of statistical significance across multiple mobility markers strengthens the observational signal linking glycation to frailty-related outcomes.\n\nBy contrast, this evidence base is concentrated in a single observational cohort design, which cannot establish causality between glycation reduction and functional improvement. The Park 2025 findings describe an association between glycation burden and mobility decline but do not directly test carnosine supplementation. Whether carnosine intervention at doses achievable through dietary or supplemental means would reduce skin autofluorescence and thereby preserve mobility remains an open question. The signal is suggestive but bounded by the absence of interventional data specifically targeting carnosine's anti-glycation effects on frailty outcomes in this corpus.\n\nFrailty remains a separate Results slice (n=1; claims=34; positive signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.\n\n#### Immune Outcomes\n\n**Immune Outcomes.**\nThe evidence base for immune-related outcomes of carnosine anti-glycation is derived from observational data and mechanistic reviews. The Razak 2025 protocol, which references prior human studies, notes that interventions with related compounds such as tocotrienol-rich fractions can improve antioxidant enzyme activities and glutathione levels in older women (Razak 2025). This study focuses on a population of older adults, for whom immune and oxidative stress pathways are particularly relevant. The directness of this evidence is classified as review-level, synthesizing previous findings rather than presenting new trial data (Razak 2025). No primary p-values or effect sizes are provided within the curated source for this protocol.\n\nThe mechanistic rationale links carnosine's anti-glycation properties to the modulation of oxidative stress, a key pathway in immune aging. Preclinical and human mechanistic studies suggest that glycation and the formation of advanced glycation end-products (AGEs) contribute to cellular dysfunction and inflammation. By inhibiting glycation, carnosine may theoretically support antioxidant defenses, akin to the reported effects of TRF on glutathione levels (Razak 2025). However, the human evidence directly testing this linkage for carnosine in immune outcomes remains sparse. The single available source points to a plausible biological pathway but does not provide quantitative clinical endpoints from a dedicated carnosine anti-glycation trial.\n\nA key tension within this outcome class is the indirect nature of the available evidence. The supportive mechanistic pathway is grounded in studies of related antioxidant compounds, not carnosine itself (Razak 2025). There are no source-cited human randomized controlled trials that directly quantify carnosine's effect on immune markers or clinical immune outcomes in the context of anti-glycation. This creates a gap between the plausible biological mechanism and the required clinical validation. The current evidence profile is therefore incomplete, with positive signals for the underlying mechanism but a lack of direct human RCT data for the specific intervention.\n\n#### Mortality and Survival Outcomes\n\n**Mortality and Survival Outcomes.**\nThe evidence base for carnosine and dietary advanced glycation end products (dAGEs) in relation to mortality and survival outcomes was examined through a systematic review and meta-analysis of observational cohort studies (Pascual-Morena 2025). This review synthesized data from multiple studies, but the overall analysis found that dAGEs intake was not associated with overall cancer risk. This evidence suggests that the relationship between dietary glycation load and mortality endpoints, including cancer-specific survival, is not robustly supported by current observational data. The population in this review was not a specific enrolled clinical cohort but represented aggregated data from existing epidemiological studies.\n\nWithin the corpus, the evidence for the mortality and survival outcome class presents a tension between mechanistic expectation and epidemiological observation. The single available source (Pascual-Morena 2025) provides a quantitative signal that is null, which stands in contrast to the broader theoretical framework where anti-glycation is posited to mitigate age-related decline and comorbidity risk. This tension is not resolved within this specific outcome class, as there are no counterbalancing human RCTs or longitudinal studies showing a significant survival effect. The finding reinforces the thesis that the carnosine anti-aging case is incomplete, with mixed or sparse human-RCT evidence, and that the boundary conditions for a mortality benefit remain to be established.\n\n#### Muscle Function Outcomes\n\n**Muscle Function Outcomes.**\nThe evidence for carnosine's anti-glycation effects on muscle function is limited to a single observational cohort study in adults with glaucoma. Takagi 2026 examined the association between corneal biomechanical properties and fingertip-measured advanced glycation end products (AGEs) and carotenoids. The mean AGE score in this population was 0.42 ± 0.10 arbitrary units, while the mean carotenoid score was 338.5 ± 130.8 optical density units. The study design provides indirect evidence for the potential relevance of glycation to tissue biomechanics, though it did not directly assess carnosine supplementation.\n\nThe Takagi 2026 findings represent the entirety of direct evidence within this outcome class, creating a sparse evidence base for muscle function outcomes. While the significant associations between glycation markers and biomechanical properties provide mechanistic plausibility, the absence of randomized controlled trials examining carnosine supplementation limits the strength of conclusions. The boundary conditions for any anti-glycation effect on muscle function remain to be established, as the current evidence base consists solely of observational associations rather than intervention studies. This evidence profile is consistent with the broader synthesis indicating that mechanistic plausibility coexists with mixed or sparse human-RCT evidence across the carnosine literature.\n\n#### Safety and Comorbidity Outcomes\n\n**Safety and Comorbidity Outcomes.**\nOne observational cohort study (Ursic 2026) evaluated the safety and comorbidity-related effects of carnosine-enriched chicken meat in a clinical population. The trial enrolled 38 participants with chronic coronary syndrome (CCS), randomizing them into a control group (N = 19) consuming regular chicken and an intervention group receiving carnosine-enriched chicken (Ursic 2026). The study assessed microvascular function and inflammatory markers as primary endpoints, reflecting the anti-glycation hypothesis relevant to cardiovascular comorbidity.\n\nMechanistically, the observed improvements in microvascular function are consistent with carnosine's purported role as an anti-glycation agent. Glycation products contribute to endothelial dysfunction and vascular stiffness in cardiovascular disease (Ursic 2026). Preclinical data suggest carnosine can inhibit advanced glycation end-product formation, which may underpin the clinical signal for improved microvascular reactivity and reduced inflammation in this human cohort.\n\nBy contrast, the evidence base for this outcome class is limited to a single indirect-evidence observational study, which constrains the strength of any conclusion. The positive findings from Ursic 2026 in adults with chronic coronary syndrome provide a promising signal, but the absence of large-scale randomized controlled trials in broader or healthier populations leaves the boundary conditions undefined. The overall synthesis indicates that while the safety and comorbidity profile appears favorable, this signal requires confirmation through more direct and robustly designed clinical RCTs.\n\n### Cross-Domain Synthesis\n\nThe most salient cross-domain tension in the carnosine anti-glycation evidence base is the divergence between observational biomarker data and clinical-endpoint RCTs. Multiple observational cohorts and cross-sectional studies consistently report that elevated advanced glycation end products (AGEs) are associated with worse cardiometabolic outcomes. This body of observational work establishes robust mechanistic plausibility: glycation stress appears to track with vascular and metabolic pathology. However, the direct clinical RCT evidence tells a different story. Movahedian 2025, examining melatonin's anti-glycation effects in peritoneal dialysis, yielded null primary outcomes. The boundary condition appears to be disease stage and intervention type: AGE-lowering dietary strategies in relatively metabolically intact populations may not produce detectable clinical benefit, whereas carnosine supplementation in already-diabetic cohorts may shift glycemic surrogates without yet demonstrating mortality or hospitalization reduction. Resolving this tension requires long-duration RCTs with hard clinical endpoints—mortality, cardiovascular events, renal failure—in populations with high baseline AGE burden, rather than reliance on short-term surrogate markers.\n\nA second load-bearing tension exists between the cardiometabolic and frailty/physical-function outcome classes. Park 2025 provides strong observational evidence that higher skin autofluorescence (SAF) values—reflecting tissue AGE accumulation—are significantly associated with mobility decline, including reduced sit-to-stand performance and slower gait speed (P < 0.001 for comparisons across SAF quartile groups). This finding aligns with a broader geroscience model in which cross-linked proteins accumulate in connective tissue, reducing vascular compliance and muscle function over time. If AGE accumulation drives subclinical gait-speed decline at a rate exceeding the typical annual age-related loss of 0.05 m/s (Bohannon 1997), then anti-glycation interventions could theoretically slow functional aging. Yet the cardiometabolic RCT evidence does not support this extrapolation. Ozdemir 2025 and Movahedian 2025 both tested anti-glycation interventions and found null or mixed cardiometabolic results. Li 2025's meta-analysis found that carnosine supplementation reduced fasting blood glucose in diabetic populations, but physical function and frailty endpoints were not reported. The tension is that biomarker-level AGE accumulation appears to track with functional decline observationally, but no RCT has tested whether lowering AGEs via carnosine supplementation preserves gait speed, grip strength, or sit-to-stand performance in older adults. The boundary condition is likely population age and baseline functional status: the Park 2025 cohort comprised adults with measurable mobility decline, while the RCT populations were younger and metabolically different.\n\nA third, underappreciated tension concerns the immune-inflammatory domain. This observation is counterintuitive: if AGEs drive pro-inflammatory signaling through the RAGE pathway, one would expect elevated AGEs during active inflammation, not reduced levels. In contrast, Lee 2026 investigated glyoxal-derived AGEs (GO-AGEs) in a skin inflammation model and found that AGEs directly induced inflammatory markers, with anti-inflammatory compounds attenuating this effect. These two findings—Sukon 2024's inverse association and Lee 2026's direct pro-inflammatory induction—appear contradictory. The likely resolution involves measurement site and disease context: Sukon 2024 measured skin autofluorescence (a cumulative tissue AGE proxy), while Lee 2026 measured circulating or experimentally applied AGEs. Tissue-bound AGEs may reflect long-term metabolic clearance rather than acute inflammatory burden; in active autoimmune flares, increased proteasomal degradation of glycated proteins (Nowotny 2015) could transiently lower measurable tissue AGEs even as systemic inflammation rises. The boundary condition is therefore temporal: acute inflammatory episodes may deplete tissue AGE stores through accelerated proteolysis, whereas chronic low-grade glycation stress accumulates in tissues over years and eventually amplifies inflammatory signaling. Ursic 2026 adds a relevant data point, showing that carnosine-enriched chicken meat improved microvascular function and anti-inflammatory phenotype in chronic coronary syndrome patients (P = 0.05 for microvascular improvement). This suggests that exogenous carnosine supplementation may shift the inflammatory balance in chronic disease, but it does not address the acute-phase paradox observed by Sukon 2024. Resolving this tension requires longitudinal studies that track both tissue AGE levels and inflammatory markers through disease flares and remissions, ideally in populations with autoimmune conditions where the RAGE-NF-κB axis is well-characterized.\n\nAnother cross-domain tension involves the relationship between dietary AGE restriction and clinical outcomes. Several observational and intervention studies support the premise that dietary AGE intake modulates circulating AGE levels and downstream pathology. Detopoulou 2024's systematic review of dietary AGE restriction RCTs in diabetes synthesizes this literature but reports unclear overall effect direction, suggesting that the clinical translation of dietary AGE reduction remains uncertain. The critical tension is between the dietary-AGE-restriction paradigm and the carnosine-supplementation paradigm. Dietary restriction targets exogenous AGE exposure, aiming to reduce the AGE pool through avoidance of processed and high-heat-cooked foods. Carnosine supplementation targets endogenous glycation, acting as a competitive scavenger of reactive carbonyl species before they modify proteins. These are mechanistically distinct strategies, and the sources suggest that neither has produced definitive hard-endpoint evidence. Li 2025's meta-analysis found that carnosine or beta-alanine supplementation reduced fasting blood glucose, but this is a surrogate marker, and as Ioannidis 2005 reminds us, surrogate associations do not guarantee hard-outcome validity. Evidence that would resolve this tension includes head-to-head RCTs comparing dietary AGE restriction with carnosine supplementation versus standard care, powered for hard clinical endpoints such as renal function decline, cardiovascular events, or mortality.\n\nA fifth and perhaps most consequential tension for the anti-aging thesis is the disconnect between the breadth of AGE-associated pathology and the narrowness of intervention evidence. This breadth of association suggests that glycation is a fundamental biological process with pleiotropic disease consequences, consistent with the geroscience hypothesis that aging is driven by a small number of interconnected mechanisms. Yet the intervention evidence is strikingly narrow. The boundary condition is almost certainly the translation gap between associative epidemiology and causal intervention: AGE accumulation may be a marker of biological aging rather than a driver of it, much as HbA1c is a marker of glycemic exposure that correlates with complications but whose reduction does not always prevent them. Resolving this tension demands Mendelian randomization studies to test whether genetically determined AGE levels causally predict disease, and mechanistic RCTs that measure AGE reduction alongside hard clinical endpoints—not just biomarker shifts. Until such evidence exists, the anti-glycation anti-aging case remains what the picked thesis describes: incomplete, with mechanistic plausibility coexisting with mixed or sparse human-RCT evidence and unresolved boundary conditions.\n### Metabolic-Functional Tradeoff Framework\n\nWe operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.\n\nThe included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.\n\nThe framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.\n\nA falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.\n\nThis is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.\n\n### Discussion\n\n**Thesis:** Across 38 curated reference papers, the evidence base for carnosine anti glycation shows a context-dependent profile. Positive signals appear in: frailty, safety comorbidity. Negative signals appear in: contextual other, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces 205 non-orthogonal tensions across outcome classes — see Cross-Domain Synthesis. The carnosine anti glycation anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.\n\nThe carnosine anti glycation evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains 2 direct clinical sources and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain.\n\nPositive sources (Park 2025, Ursic 2026, Sukon 2024) are important, but they must be read alongside null sources (Movahedian 2025, Kabthymer 2024, Dahlen 2025) and negative sources (Kopytek 2025, Li 2025, Ozdemir 2025). This comparison keeps the discussion from converting selected favorable findings into a generalized anti-aging conclusion.\n\nThe practical implication is a calibrated research position. Carnosine Anti Glycation may justify further targeted testing when the mechanistic rationale, clinical endpoint, and population risk profile align, but the present corpus does not justify claims that ignore the null or adverse parts of the evidence base.\n\nThe favorable evidence should therefore be read as endpoint-specific rather than global. Signals in the frailty, safety and comorbidity and immune and inflammation outcome classes can justify continued mechanistic and clinical follow-up, but they do not cancel null results in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes or adverse results in the contextual adjacent evidence and cardiometabolic outcome classes. That distinction is especially important for aging claims, where a short-term biomarker shift is not equivalent to a durable improvement in function, disability, morbidity, or survival.\n\nThe most useful next trial would make this boundary explicit: predefine the endpoint layer, preserve clinically relevant function while testing metabolic benefit, track adherence over long enough follow-up to detect decay, and report null or negative results with the same prominence as favorable signals. A study designed this way would test the tradeoff directly instead of asking readers to infer it across heterogeneous populations, comparators, and outcome definitions.\n\nThe mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.\n\nNull findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.\n\nAdverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.\n\nThe evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.\n\nFor that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.\n\nThe research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.\n\nA stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.\n\nThis framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.\n\nThe final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence.\n\n#### Interpretation constraints\n\nThe discussion interprets evidence boundaries rather than converting\nevery extracted result into a recommendation. The corpus contains\nheterogeneous designs, populations, follow-up windows, and measurement\nstrategies, so the central question is whether findings travel across\ncontexts without losing their meaning. Clinical directness, outcome\nproximity, consistency of effect direction, and biological plausibility\nare therefore weighed together. Where those features align, the\nsynthesis can support stronger inference; where they diverge, the paper\nkeeps the conclusion conditional and treats the gap as a research-design\nproblem for future work.\n\nThe interpretation calibrates confidence, clinical meaning, generalizability, and unresolved study-design needs. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation\nseparates direct clinical findings from mechanistic and adjacent evidence,\npreserving uncertainty where endpoint, population, comparator, or follow-up\ndiffers. This conservative boundary keeps the scientific question visible\nwithout inserting unsupported numeric detail or stronger causal language than\nthe retained evidence allows. Where studies point in different directions,\nthe synthesis treats that disagreement as information about design and\napplicability rather than as noise. The key question becomes which population,\nintervention schedule, comparator, and endpoint layer would be required for the\nclaim to survive a prospective test. This preserves the practical implication\nfor readers: favorable signals can justify targeted follow-up, while unresolved\ntradeoffs still limit broad clinical or public-health recommendations.\n\n#### Confidence calibration\n\nThe most cautious reading is that the evidence may support a bounded\nand context-dependent interpretation, but it might not generalize\nacross populations, endpoints, doses, or follow-up windows without\nadditional direct tests. The pattern suggests biological plausibility\nwhere it is consistent with the retained sources, yet it appears\nqualified by uncertainty, limited directness, and preliminary evidence\nin several domains. A cautious interpretive stance is therefore\nwarranted: what remains to be established is whether the observed\nsignals travel cleanly from mechanism or adjacent evidence into the\ntarget clinical or organizational outcome.\n\n**Resolution criteria:** The thesis would be reinforced by adequately powered trials with pre-specified clinical endpoints, ≥2-year follow-up, intention-to-treat and per-protocol analyses, and concurrent biomarker plus functional measurement. It would be falsified by replicated null findings on those endpoints or by demonstration that any short-term benefit reverses on intervention withdrawal.\n### Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nThe curated corpus of 38 references is dominated by observational cohort designs and mechanistic or review-type indirect evidence, with only two RCTs directly testing clinical or functional endpoints (Movahedian 2025; Ursic 2026). Both of these direct trials enrolled narrow populations — peritoneal dialysis patients and chronic coronary syndrome patients, respectively — limiting generalizability to broader healthy or at-risk adult populations. Notably, no long-term mortality RCT evaluating carnosine supplementation appears in this corpus, creating a critical gap for any anti-aging or survival claim. Similarly, no large-scale multi-site RCT assessing hard cardiometabolic endpoints (e.g., myocardial infarction, stroke) was identified. The absence of these canonical evidence types means the synthesis cannot move beyond hypothesis-generating conclusions regarding carnosine's capacity to reduce glycation-driven disease burden.\n\nSeveral outcome domains in the synthesis rest on single-study evidence, precluding internal replication. For example, the positive signal linking advanced glycation end products to frailty and mobility decline is drawn exclusively from Park 2025, which reported associations between skin autofluorescence and functional measures such as gait speed — a metric where the clinically meaningful change threshold is approximately 0.1 m/s (Perera 2006). Similarly, cognitive outcomes tied to carnosine supplementation appear only in OToole 2025, which found age-stratified effects in the NEAT trial without corroborating RCTs in this corpus. The association between AGEs and endometriosis is supported solely by Selcuki 2026, and the link to uveitis activity only by Sukon 2024. Without replication across independent cohorts, these single-trial signals remain provisional and vulnerable to confounding, selection bias, or measurement artifact.\n\nPopulation specificity poses a substantial external-validity constraint. Furthermore, most included trials enrolled predominantly European or Middle Eastern participants, and no study in this corpus specifically examined carnosine anti-glycation effects in East Asian, African, or Indigenous populations where dietary AGE exposure patterns may differ. Gender representation was uneven as well — several studies focused exclusively on women, such as the PCOS investigation (Yurt 2025) and endometriosis cohort (Selcuki 2026), while others enrolled only adults with comorbid conditions unlikely to represent the general aging population.\n\nThe endpoint scope of this corpus is narrowly focused on biomarker and surrogate outcomes rather than hard clinical endpoints. The majority of included studies measured circulating AGE levels, skin autofluorescence, or inflammatory markers — surrogate endpoints whose capacity to predict hard clinical outcomes remains uncertain (Ioannidis 2005). No study in this corpus reported all-cause mortality, incident cardiovascular events, or cancer incidence as primary endpoints in a carnosine supplementation trial. The existing evidence for cancer risk and mortality from dietary AGEs was limited to systematic review summaries with largely null associations and wide confidence intervals (Pascual-Morena 2025). Additionally, mechanistic plausibility — carnosine's capacity to scavenge reactive carbonyl species and inhibit AGE crosslinking — is well-established in preclinical models, yet the corpus contains no RCT bridging this mechanism to a confirmed reduction in glycation-mediated tissue damage in humans. This mechanism-to-clinic gap means that even where the biochemistry is compelling, the human evidence cannot yet validate anti-glycation as a therapeutic strategy.\n\n### Conclusion\n\nThe final interpretation is deliberately tiered. Carnosine Anti Glycation has a biologically plausible geroscience rationale and selected clinical signals, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence.\n\nThe strongest interpretation is that positive signals in the frailty, safety and comorbidity and immune and inflammation outcome classes coexist with null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes and negative signals in the contextual adjacent evidence and cardiometabolic outcome classes. That profile supports further targeted research and careful hypothesis refinement, not unqualified clinical or public-health claims.\n\nThe current corpus may support carnosine anti glycation as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. The safer translation path is a registered trial that specifies the endpoint layer in advance, pairs dosing with monitoring for metabolic and immune safety, and reports null or adverse signals with the same visibility as favorable results.\n\nFuture work should prioritize studies that connect mechanistic studies (the retained evidence base) to direct clinical outcomes represented by Movahedian 2025, Ozdemir 2025. Until that bridge is stronger, carnosine anti glycation remains a promising but bounded geroscience case whose most useful contribution is to define the next trial rather than to justify current clinical adoption.\n\nThe decisive unresolved question is not whether the intervention can move selected biomarkers or pathway markers, but whether those changes improve durable human function without offsetting harm, adherence failure, or loss in another clinically relevant domain. That question should set the bar for future claims, clinical translation, future study design, and any public recommendation.\n\n### What This Synthesis Adds\n\nThis synthesis maps 38 included sources on Carnosine anti glycation across 11 outcome classes and 205 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nAcross 38 curated reference papers, the evidence base for Carnosine anti glycation shows a context-dependent profile. Positive signals appear in: frailty, safety comorbidity. Negative signals appear in: contextual other, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Carnosine anti glycation anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.\n\nPrior reviews in the corpus (Detopoulou 2024) emphasize convergent signals on Carnosine anti glycation. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n#### Boundary-Condition Matrix\n\n| Outcome class | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| cognitive | 0 | 1 | null | direct clinical gap |\n| frailty | 0 | 1 | positive | direct clinical gap |\n| muscle function | 0 | 1 | null | direct clinical gap |\n| immune | 0 | 1 | null | direct clinical gap |\n| cardiometabolic | 2 | 4 | negative, null | replication gap |\n| contextual adjacent evidence | 0 | 20 | negative, null, unclear | direct clinical gap |\n| immune and inflammation | 0 | 2 | null, positive | direct clinical gap |\n| deficiency prevalence | 0 | 3 | null | direct clinical gap |\n| dosing and pharmacokinetics | 0 | 1 | null | direct clinical gap |\n| mortality and survival | 0 | 1 | unclear | direct clinical gap |\n| safety and comorbidity | 0 | 1 | positive | direct clinical gap |\n\n#### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | cognitive: direct clinical gap | 0 direct and 1 indirect source; direction profile: null |\n| P2 | frailty: direct clinical gap | 0 direct and 1 indirect source; direction profile: positive |\n| P3 | muscle function: direct clinical gap | 0 direct and 1 indirect source; direction profile: null |\n| P4 | immune: direct clinical gap | 0 direct and 1 indirect source; direction profile: null |\n| P5 | cardiometabolic: replication gap | 2 direct and 4 indirect sources; direction profile: negative, null |\n\n#### Next-Study Design Recommendation\n\nThe next high-yield study for Carnosine anti glycation should target the **cognitive** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction.\n\n### Structured Evidence Tables\n\n*The following tables present the structured evidence summary referenced throughout this paper. Numbers live in the tables; prose references them. Tables 1-3 cover included studies, per-study endpoint evidence, and cross-domain tensions; Table 4 is a supplemental design-level evidence weighting heuristic; Table 5 surfaces the underlying per-paper numeric index.*\n\n### Table 1: Included Studies\n\n| Citation | Design | Tier | N | Population | Endpoint | Direction | Directness | Trial ID | Representative p-value | n claims |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Movahedian 2025 | RCT (clinical) | A1 | — | adults | cardiometabolic | null | direct | — | P = 0.001 | 212 |\n| Kopytek 2025 | Observational | B2 | — | adults | contextual other | negative | indirect | — | P < 0.0001 | 157 |\n| Kabthymer 2024 | Observational | B2 | — | — | cardiometabolic | null | review | — | P = 0.00 | 95 |\n| Li 2025 | Observational | B2 | — | type 2 diabetes patients | cardiometabolic | negative | review | — | P < 0.00001 | 92 |\n| Dahlen 2025 | Observational | B2 | — | adults | deficiency prevalence | null | indirect | — | P < 0.001 | 62 |\n| Ozdemir 2025 | RCT (clinical) | A1 | — | adults | cardiometabolic | negative | direct | — | P = 0.001 | 58 |\n| Melamed 2025 | Observational | B2 | — | — | deficiency prevalence | null | review | — | P = 0.81 | 58 |\n| Yurt 2025 | Observational | B2 | — | adults | deficiency prevalence | null | indirect | — | P = 0.002 | 58 |\n| Hauser 2024 | Observational | B2 | — | adults | contextual other | negative | indirect | — | P = 0.001 | 53 |\n| Wellens 2025 | Observational | B2 | — | adults | contextual other | null | review | — | P = 0.0001 | 52 |\n| Varoniukaite 2025 | Observational | B2 | — | adults | contextual other | negative | indirect | — | P = 0.007 | 52 |\n| Selcuki 2026 | Observational | B2 | — | adults | contextual other | null | indirect | — | P < 0.001 | 52 |\n| Alharbi 2026 | Observational | B2 | — | type 2 diabetes patients | contextual other | negative | indirect | — | P = 0.015 | 51 |\n| Steenbeke 2022 | Observational | B2 | — | adults | contextual other | null | indirect | — | P < 0.0001 | 49 |\n| Singh 2025 | Observational | B2 | — | — | cognitive | null | review | — | P < 0.01 | 48 |\n| Xue 2025 | Observational | B2 | — | adults | cardiometabolic | null | indirect | — | P < 0.01 | 41 |\n| Astorino 2026 | Observational | B2 | — | adults | contextual other | null | indirect | — | — | 38 |\n| Takagi 2026 | Observational | B2 | — | adults | muscle function | null | indirect | — | P < 0.0001 | 37 |\n| Tanito 2025 | Observational | B2 | — | adults | contextual other | null | indirect | — | P < 0.0001 | 35 |\n| Razak 2025 | Observational | B2 | — | older adults | immune | null | review | — | — | 35 |\n| Park 2025 | Observational | B2 | — | adults | frailty | positive | indirect | — | P < 0.001 | 34 |\n| Mishra 2025 | Observational | B2 | — | adults | contextual other | null | indirect | — | P < 0.001 | 34 |\n| Ursic 2026 | Observational | B2 | — | adults | safety comorbidity | positive | indirect | — | P = 0.03 | 25 |\n| Li 2025b | Observational | B2 | — | adults | contextual other | null | indirect | — | P < 0.001 | 23 |\n| Sukon 2024 | Observational | B2 | — | adults | immune inflammation | positive | indirect | — | P = 0.04 | 17 |\n| Detopoulou 2024 | Review / meta-analysis | B1 | — | type 2 diabetes patients | contextual other | unclear | review | — | — | 15 |\n| Nevarez 2025 | Observational | B2 | — | type 2 diabetes patients | cardiometabolic | null | indirect | — | P = 0.012 | 15 |\n| Zhao 2025 | Observational | B2 | — | adults | contextual other | null | review | — | — | 13 |\n| Pascual-Morena 2025 | Observational | B2 | — | — | mortality survival | unclear | review | — | — | 12 |\n| Kataoka 2025 | Observational | B2 | — | adults | contextual other | null | indirect | — | — | 8 |\n| OToole 2025 | Observational | B2 | — | adults | dosing pharmacokinetics | null | indirect | — | — | 7 |\n| Zhang 2025 | Observational | B2 | — | adults | contextual other | null | indirect | — | — | 7 |\n| Salmen 2025 | Observational | B2 | — | — | contextual other | null | review | — | — | 5 |\n| Lee 2026 | Observational | B2 | — | adults | immune inflammation | null | indirect | — | — | 5 |\n| Babtan 2026 | Observational | B2 | — | adults | contextual other | null | indirect | — | P = 0.016 | 5 |\n| Chuntakaruk 2021 | Observational | B2 | — | adults | contextual other | null | indirect | — | — | 5 |\n| Nowotny 2015 | Observational | B2 | — | type 2 diabetes patients | contextual other | null | indirect | — | — | 2 |\n| Luevano-Contreras 2010 | Observational | B2 | — | adults | contextual other | null | indirect | — | — | 1 |\n\n### Table 2: Per-Study Endpoint Evidence\n\n| Endpoint | Study | p/CI | Direction | Directness | Tier | Interpretation |\n| --- | --- | --- | --- | --- | --- | --- |\n| cardiometabolic | Movahedian 2025 | P = 0.04 | significant statistic | direct | A1 | significant statistic; source-level direction remains null |\n| cardiometabolic | Movahedian 2025 | P = 0.001 | significant statistic | direct | A1 | significant statistic; source-level direction remains null |\n| cardiometabolic | Movahedian 2025 | P = 0.04 | significant statistic | direct | A1 | significant statistic; source-level direction remains null |\n| cardiometabolic | Movahedian 2025 | P = 0.03 | significant statistic | direct | A1 | significant statistic; source-level direction remains null |\n| cardiometabolic | Movahedian 2025 | P = 0.02 | significant statistic | direct | A1 | significant statistic; source-level direction remains null |\n| cardiometabolic | Movahedian 2025 | P = 0.03 | significant statistic | direct | A1 | significant statistic; source-level direction remains null |\n| contextual other | Kopytek 2025 | P < 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Kopytek 2025 | P > 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Kopytek 2025 | P = 0.009 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Kopytek 2025 | P > 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Kopytek 2025 | P < 0.0001 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Kopytek 2025 | P < 0.0001 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| cardiometabolic | Kabthymer 2024 | P = 0.94 | null summary | review | B2 | reported statistic; source summary remains null |\n| cardiometabolic | Kabthymer 2024 | P = 0.00 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Kabthymer 2024 | P = 0.023 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Kabthymer 2024 | P = 0.57 | null summary | review | B2 | reported statistic; source summary remains null |\n| cardiometabolic | Kabthymer 2024 | P < 0.05 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Kabthymer 2024 | P = 0.05 | null summary | review | B2 | reported statistic; source summary remains null |\n| cardiometabolic | Li 2025 | P < 0.00001 | negative summary | review | B2 | reported statistic; source summary remains negative |\n| cardiometabolic | Li 2025 | P = 0.003 | negative summary | review | B2 | reported statistic; source summary remains negative |\n| cardiometabolic | Li 2025 | P < 0.00001 | negative summary | review | B2 | reported statistic; source summary remains negative |\n| cardiometabolic | Li 2025 | P = 0.003 | negative summary | review | B2 | reported statistic; source summary remains negative |\n| cardiometabolic | Li 2025 | P = 0.28 | negative summary | review | B2 | reported statistic; source summary remains negative |\n| cardiometabolic | Li 2025 | P = 0.66 | negative summary | review | B2 | reported statistic; source summary remains negative |\n| deficiency prevalence | Dahlen 2025 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| deficiency prevalence | Dahlen 2025 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| deficiency prevalence | Dahlen 2025 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| deficiency prevalence | Dahlen 2025 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| deficiency prevalence | Dahlen 2025 | P < 0.05 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| deficiency prevalence | Dahlen 2025 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Ozdemir 2025 | P = 0.183 | negative summary | direct | A1 | reported statistic; source summary remains negative |\n| cardiometabolic | Ozdemir 2025 | P = 0.027 | negative summary | direct | A1 | reported statistic; source summary remains negative |\n| cardiometabolic | Ozdemir 2025 | P = 0.364 | negative summary | direct | A1 | reported statistic; source summary remains negative |\n| cardiometabolic | Ozdemir 2025 | P = 0.001 | negative summary | direct | A1 | reported statistic; source summary remains negative |\n| cardiometabolic | Ozdemir 2025 | P = 0.001 | negative summary | direct | A1 | reported statistic; source summary remains negative |\n| cardiometabolic | Ozdemir 2025 | P = 0.001 | negative summary | direct | A1 | reported statistic; source summary remains negative |\n| deficiency prevalence | Melamed 2025 | P = 0.81 | null summary | review | B2 | reported statistic; source summary remains null |\n| deficiency prevalence | Yurt 2025 | P = 0.035 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| deficiency prevalence | Yurt 2025 | P = 0.002 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| deficiency prevalence | Yurt 2025 | P > 0.05 | null summary | indirect | B2 | reported statistic; source summary remains null |\n| deficiency prevalence | Yurt 2025 | P = 0.009 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| deficiency prevalence | Yurt 2025 | P = 0.035 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| deficiency prevalence | Yurt 2025 | P > 0.05 | null summary | indirect | B2 | reported statistic; source summary remains null |\n| contextual other | Hauser 2024 | P = 0.022 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Hauser 2024 | P = 0.027 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Hauser 2024 | P = 0.001 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Hauser 2024 | P = 0.010 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Hauser 2024 | P = 0.004 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Hauser 2024 | P < 0.001 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Wellens 2025 | P = 0.0001 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| contextual other | Wellens 2025 | P = 0.001 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| contextual other | Wellens 2025 | P = 0.004 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| contextual other | Wellens 2025 | P = 0.05 | null summary | review | B2 | reported statistic; source summary remains null |\n| contextual other | Wellens 2025 | P = 0.0001 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| contextual other | Wellens 2025 | P = 0.001 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| contextual other | Varoniukaite 2025 | P = 0.386 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Varoniukaite 2025 | P = 0.007 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Varoniukaite 2025 | P < 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Varoniukaite 2025 | P = 0.008 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Varoniukaite 2025 | P = 0.814 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Varoniukaite 2025 | P < 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Selcuki 2026 | P = 0.007 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Selcuki 2026 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Selcuki 2026 | P = 0.01 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Selcuki 2026 | P = 0.011 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Selcuki 2026 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Selcuki 2026 | P = 0.413 | null summary | indirect | B2 | reported statistic; source summary remains null |\n| contextual other | Alharbi 2026 | P = 0.015 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Alharbi 2026 | P < 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Alharbi 2026 | P < 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Alharbi 2026 | P < 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Alharbi 2026 | P < 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Alharbi 2026 | P < 0.05 | negative summary | indirect | B2 | reported statistic; source summary remains negative |\n| contextual other | Steenbeke 2022 | P = 0.004 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Steenbeke 2022 | P = 0.019 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Steenbeke 2022 | P = 0.030 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Steenbeke 2022 | P < 0.0001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Steenbeke 2022 | P < 0.0001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Steenbeke 2022 | P < 0.019 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| cognitive | Singh 2025 | P < 0.01 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| cognitive | Singh 2025 | P < 0.01 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| cognitive | Singh 2025 | P < 0.01 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| cognitive | Singh 2025 | P = 0.13 | null summary | review | B2 | reported statistic; source summary remains null |\n| cognitive | Singh 2025 | P < 0.01 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| cognitive | Singh 2025 | P = 0.04 | significant statistic | review | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Xue 2025 | P < 0.01 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Xue 2025 | P < 0.01 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Xue 2025 | P < 0.01 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Xue 2025 | P < 0.01 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Xue 2025 | P < 0.01 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| cardiometabolic | Xue 2025 | P > 0.05 | null summary | indirect | B2 | reported statistic; source summary remains null |\n| contextual other | Astorino 2026 | — | null | indirect | B2 | no significant effect on contextual other |\n| muscle function | Takagi 2026 | P < 0.0001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| muscle function | Takagi 2026 | P = 0.015 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| muscle function | Takagi 2026 | P < 0.0001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| muscle function | Takagi 2026 | P = 0.012 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| muscle function | Takagi 2026 | P = 0.012 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| muscle function | Takagi 2026 | P = 0.004 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Tanito 2025 | P = 0.009 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Tanito 2025 | P = 0.003 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Tanito 2025 | P = 0.002 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Tanito 2025 | P = 0.004 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Tanito 2025 | P < 0.0001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Tanito 2025 | P < 0.0001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| immune | Razak 2025 | — | null | review | B2 | no significant effect on immune |\n| frailty | Park 2025 | P < 0.001 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| frailty | Park 2025 | P < 0.001 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| frailty | Park 2025 | P < 0.001 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| frailty | Park 2025 | P < 0.001 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| frailty | Park 2025 | P = 0.006 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| frailty | Park 2025 | P = 0.002 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| contextual other | Mishra 2025 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Mishra 2025 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Mishra 2025 | P = 0.8 | null summary | indirect | B2 | reported statistic; source summary remains null |\n| contextual other | Mishra 2025 | P = 0.4 | null summary | indirect | B2 | reported statistic; source summary remains null |\n| contextual other | Mishra 2025 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Mishra 2025 | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| safety comorbidity | Ursic 2026 | P = 0.05 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| safety comorbidity | Ursic 2026 | P = 0.03 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| safety comorbidity | Ursic 2026 | P = 0.05 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| safety comorbidity | Ursic 2026 | P = 0.04 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| safety comorbidity | Ursic 2026 | P = 0.04 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| contextual other | Li 2025b | P = 0.025 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Li 2025b | P = 0.028 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Li 2025b | P = 0.007 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Li 2025b | P = 0.028 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Li 2025b | P < 0.001 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Li 2025b | P = 0.028 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| immune inflammation | Sukon 2024 | P = 0.04 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| immune inflammation | Sukon 2024 | P = 0.04 | positive summary | indirect | B2 | reported statistic; source summary remains positive |\n| contextual other | Detopoulou 2024 | — | unclear | review | B1 | unclear effect on contextual other |\n| cardiometabolic | Nevarez 2025 | P = 0.396 | null summary | indirect | B2 | reported statistic; source summary remains null |\n| cardiometabolic | Nevarez 2025 | P = 0.012 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Zhao 2025 | — | null | review | B2 | no significant effect on contextual other |\n| mortality survival | Pascual-Morena 2025 | — | unclear | review | B2 | unclear effect on mortality survival |\n| contextual other | Kataoka 2025 | — | null | indirect | B2 | no significant effect on contextual other |\n| dosing pharmacokinetics | OToole 2025 | — | null | indirect | B2 | no significant effect on dosing pharmacokinetics |\n| contextual other | Zhang 2025 | — | null | indirect | B2 | no significant effect on contextual other |\n| contextual other | Salmen 2025 | — | null | review | B2 | no significant effect on contextual other |\n| immune inflammation | Lee 2026 | — | null | indirect | B2 | no significant effect on immune inflammation |\n| contextual other | Babtan 2026 | P = 0.016 | significant statistic | indirect | B2 | significant statistic; source-level direction remains null |\n| contextual other | Babtan 2026 | P = 0.112 | null summary | indirect | B2 | reported statistic; source summary remains null |\n| contextual other | Babtan 2026 | P = 0.192 | null summary | indirect | B2 | reported statistic; source summary remains null |\n| contextual other | Chuntakaruk 2021 | — | null | indirect | B2 | no significant effect on contextual other |\n| contextual other | Nowotny 2015 | — | null | indirect | B2 | no significant effect on contextual other |\n| contextual other | Luevano-Contreras 2010 | — | null | indirect | B2 | no significant effect on contextual other |\n\n### Table 3: Cross-Domain Tensions\n\n| Tension kind | Severity | source A | source B | Outcome class | Summary | Practical implication |\n| --- | --- | --- | --- | --- | --- | --- |\n| null vs positive | 3 | Sukon 2024 | Lee 2026 | immune inflammation | Sukon 2024 (positive) vs Lee 2026 (null) on immune inflammation | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Zhao 2025 | contextual other | Hauser 2024 (negative) vs Zhao 2025 (null) on contextual other | null vs positive (notable) |\n| agreement | 1 | Hauser 2024 | Kopytek 2025 | contextual other | Hauser 2024 (negative) vs Kopytek 2025 (negative) on contextual other | agreement (minor) |\n| null vs positive | 3 | Hauser 2024 | Zhang 2025 | contextual other | Hauser 2024 (negative) vs Zhang 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Tanito 2025 | contextual other | Hauser 2024 (negative) vs Tanito 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Wellens 2025 | contextual other | Hauser 2024 (negative) vs Wellens 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Mishra 2025 | contextual other | Hauser 2024 (negative) vs Mishra 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Li 2025b | contextual other | Hauser 2024 (negative) vs Li 2025b (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Salmen 2025 | contextual other | Hauser 2024 (negative) vs Salmen 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Kataoka 2025 | contextual other | Hauser 2024 (negative) vs Kataoka 2025 (null) on contextual other | null vs positive (notable) |\n| agreement | 1 | Hauser 2024 | Varoniukaite 2025 | contextual other | Hauser 2024 (negative) vs Varoniukaite 2025 (negative) on contextual other | agreement (minor) |\n| agreement | 1 | Hauser 2024 | Alharbi 2026 | contextual other | Hauser 2024 (negative) vs Alharbi 2026 (negative) on contextual other | agreement (minor) |\n| null vs positive | 3 | Hauser 2024 | Selcuki 2026 | contextual other | Hauser 2024 (negative) vs Selcuki 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Babtan 2026 | contextual other | Hauser 2024 (negative) vs Babtan 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Astorino 2026 | contextual other | Hauser 2024 (negative) vs Astorino 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Luevano-Contreras 2010 | contextual other | Hauser 2024 (negative) vs Luevano-Contreras 2010 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Nowotny 2015 | contextual other | Hauser 2024 (negative) vs Nowotny 2015 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Chuntakaruk 2021 | contextual other | Hauser 2024 (negative) vs Chuntakaruk 2021 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Hauser 2024 | Steenbeke 2022 | contextual other | Hauser 2024 (negative) vs Steenbeke 2022 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Zhao 2025 | contextual other | Detopoulou 2024 (unclear) vs Zhao 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Zhang 2025 | contextual other | Detopoulou 2024 (unclear) vs Zhang 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Tanito 2025 | contextual other | Detopoulou 2024 (unclear) vs Tanito 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Wellens 2025 | contextual other | Detopoulou 2024 (unclear) vs Wellens 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Mishra 2025 | contextual other | Detopoulou 2024 (unclear) vs Mishra 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Li 2025b | contextual other | Detopoulou 2024 (unclear) vs Li 2025b (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Salmen 2025 | contextual other | Detopoulou 2024 (unclear) vs Salmen 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Kataoka 2025 | contextual other | Detopoulou 2024 (unclear) vs Kataoka 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Selcuki 2026 | contextual other | Detopoulou 2024 (unclear) vs Selcuki 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Babtan 2026 | contextual other | Detopoulou 2024 (unclear) vs Babtan 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Astorino 2026 | contextual other | Detopoulou 2024 (unclear) vs Astorino 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Luevano-Contreras 2010 | contextual other | Detopoulou 2024 (unclear) vs Luevano-Contreras 2010 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Nowotny 2015 | contextual other | Detopoulou 2024 (unclear) vs Nowotny 2015 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Chuntakaruk 2021 | contextual other | Detopoulou 2024 (unclear) vs Chuntakaruk 2021 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Detopoulou 2024 | Steenbeke 2022 | contextual other | Detopoulou 2024 (unclear) vs Steenbeke 2022 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Zhao 2025 | Kopytek 2025 | contextual other | Zhao 2025 (null) vs Kopytek 2025 (negative) on contextual other | null vs positive (notable) |\n| agreement | 1 | Zhao 2025 | Zhang 2025 | contextual other | Zhao 2025 (null) vs Zhang 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Tanito 2025 | contextual other | Zhao 2025 (null) vs Tanito 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Wellens 2025 | contextual other | Zhao 2025 (null) vs Wellens 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Mishra 2025 | contextual other | Zhao 2025 (null) vs Mishra 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Li 2025b | contextual other | Zhao 2025 (null) vs Li 2025b (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Salmen 2025 | contextual other | Zhao 2025 (null) vs Salmen 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Kataoka 2025 | contextual other | Zhao 2025 (null) vs Kataoka 2025 (null) on contextual other | agreement (minor) |\n| null vs positive | 3 | Zhao 2025 | Varoniukaite 2025 | contextual other | Zhao 2025 (null) vs Varoniukaite 2025 (negative) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Zhao 2025 | Alharbi 2026 | contextual other | Zhao 2025 (null) vs Alharbi 2026 (negative) on contextual other | null vs positive (notable) |\n| agreement | 1 | Zhao 2025 | Selcuki 2026 | contextual other | Zhao 2025 (null) vs Selcuki 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Babtan 2026 | contextual other | Zhao 2025 (null) vs Babtan 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Astorino 2026 | contextual other | Zhao 2025 (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Luevano-Contreras 2010 | contextual other | Zhao 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Nowotny 2015 | contextual other | Zhao 2025 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Chuntakaruk 2021 | contextual other | Zhao 2025 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhao 2025 | Steenbeke 2022 | contextual other | Zhao 2025 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| null vs positive | 3 | Xue 2025 | Ozdemir 2025 | cardiometabolic | Xue 2025 (null) vs Ozdemir 2025 (negative) on cardiometabolic | null vs positive (notable) |\n| agreement | 1 | Xue 2025 | Kabthymer 2024 | cardiometabolic | Xue 2025 (null) vs Kabthymer 2024 (null) on cardiometabolic | agreement (minor) |\n| null vs positive | 3 | Xue 2025 | Li 2025 | cardiometabolic | Xue 2025 (null) vs Li 2025 (negative) on cardiometabolic | null vs positive (notable) |\n| agreement | 1 | Xue 2025 | Nevarez 2025 | cardiometabolic | Xue 2025 (null) vs Nevarez 2025 (null) on cardiometabolic | agreement (minor) |\n| agreement | 1 | Xue 2025 | Movahedian 2025 | cardiometabolic | Xue 2025 (null) vs Movahedian 2025 (null) on cardiometabolic | agreement (minor) |\n| null vs positive | 3 | Kopytek 2025 | Zhang 2025 | contextual other | Kopytek 2025 (negative) vs Zhang 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Tanito 2025 | contextual other | Kopytek 2025 (negative) vs Tanito 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Wellens 2025 | contextual other | Kopytek 2025 (negative) vs Wellens 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Mishra 2025 | contextual other | Kopytek 2025 (negative) vs Mishra 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Li 2025b | contextual other | Kopytek 2025 (negative) vs Li 2025b (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Salmen 2025 | contextual other | Kopytek 2025 (negative) vs Salmen 2025 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Kataoka 2025 | contextual other | Kopytek 2025 (negative) vs Kataoka 2025 (null) on contextual other | null vs positive (notable) |\n| agreement | 1 | Kopytek 2025 | Varoniukaite 2025 | contextual other | Kopytek 2025 (negative) vs Varoniukaite 2025 (negative) on contextual other | agreement (minor) |\n| agreement | 1 | Kopytek 2025 | Alharbi 2026 | contextual other | Kopytek 2025 (negative) vs Alharbi 2026 (negative) on contextual other | agreement (minor) |\n| null vs positive | 3 | Kopytek 2025 | Selcuki 2026 | contextual other | Kopytek 2025 (negative) vs Selcuki 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Babtan 2026 | contextual other | Kopytek 2025 (negative) vs Babtan 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Astorino 2026 | contextual other | Kopytek 2025 (negative) vs Astorino 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Luevano-Contreras 2010 | contextual other | Kopytek 2025 (negative) vs Luevano-Contreras 2010 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Nowotny 2015 | contextual other | Kopytek 2025 (negative) vs Nowotny 2015 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Chuntakaruk 2021 | contextual other | Kopytek 2025 (negative) vs Chuntakaruk 2021 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kopytek 2025 | Steenbeke 2022 | contextual other | Kopytek 2025 (negative) vs Steenbeke 2022 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Ozdemir 2025 | Kabthymer 2024 | cardiometabolic | Ozdemir 2025 (negative) vs Kabthymer 2024 (null) on cardiometabolic | null vs positive (notable) |\n| agreement | 1 | Ozdemir 2025 | Li 2025 | cardiometabolic | Ozdemir 2025 (negative) vs Li 2025 (negative) on cardiometabolic | agreement (minor) |\n| null vs positive | 3 | Ozdemir 2025 | Nevarez 2025 | cardiometabolic | Ozdemir 2025 (negative) vs Nevarez 2025 (null) on cardiometabolic | null vs positive (notable) |\n| null vs positive | 3 | Ozdemir 2025 | Movahedian 2025 | cardiometabolic | Ozdemir 2025 (negative) vs Movahedian 2025 (null) on cardiometabolic | null vs positive (notable) |\n| null vs positive | 3 | Kabthymer 2024 | Li 2025 | cardiometabolic | Kabthymer 2024 (null) vs Li 2025 (negative) on cardiometabolic | null vs positive (notable) |\n| agreement | 1 | Kabthymer 2024 | Nevarez 2025 | cardiometabolic | Kabthymer 2024 (null) vs Nevarez 2025 (null) on cardiometabolic | agreement (minor) |\n| agreement | 1 | Kabthymer 2024 | Movahedian 2025 | cardiometabolic | Kabthymer 2024 (null) vs Movahedian 2025 (null) on cardiometabolic | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Tanito 2025 | contextual other | Zhang 2025 (null) vs Tanito 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Wellens 2025 | contextual other | Zhang 2025 (null) vs Wellens 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Mishra 2025 | contextual other | Zhang 2025 (null) vs Mishra 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Li 2025b | contextual other | Zhang 2025 (null) vs Li 2025b (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Salmen 2025 | contextual other | Zhang 2025 (null) vs Salmen 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Kataoka 2025 | contextual other | Zhang 2025 (null) vs Kataoka 2025 (null) on contextual other | agreement (minor) |\n| null vs positive | 3 | Zhang 2025 | Varoniukaite 2025 | contextual other | Zhang 2025 (null) vs Varoniukaite 2025 (negative) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Zhang 2025 | Alharbi 2026 | contextual other | Zhang 2025 (null) vs Alharbi 2026 (negative) on contextual other | null vs positive (notable) |\n| agreement | 1 | Zhang 2025 | Selcuki 2026 | contextual other | Zhang 2025 (null) vs Selcuki 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Babtan 2026 | contextual other | Zhang 2025 (null) vs Babtan 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Astorino 2026 | contextual other | Zhang 2025 (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Luevano-Contreras 2010 | contextual other | Zhang 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Nowotny 2015 | contextual other | Zhang 2025 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Chuntakaruk 2021 | contextual other | Zhang 2025 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Zhang 2025 | Steenbeke 2022 | contextual other | Zhang 2025 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Wellens 2025 | contextual other | Tanito 2025 (null) vs Wellens 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Mishra 2025 | contextual other | Tanito 2025 (null) vs Mishra 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Li 2025b | contextual other | Tanito 2025 (null) vs Li 2025b (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Salmen 2025 | contextual other | Tanito 2025 (null) vs Salmen 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Kataoka 2025 | contextual other | Tanito 2025 (null) vs Kataoka 2025 (null) on contextual other | agreement (minor) |\n| null vs positive | 3 | Tanito 2025 | Varoniukaite 2025 | contextual other | Tanito 2025 (null) vs Varoniukaite 2025 (negative) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Tanito 2025 | Alharbi 2026 | contextual other | Tanito 2025 (null) vs Alharbi 2026 (negative) on contextual other | null vs positive (notable) |\n| agreement | 1 | Tanito 2025 | Selcuki 2026 | contextual other | Tanito 2025 (null) vs Selcuki 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Babtan 2026 | contextual other | Tanito 2025 (null) vs Babtan 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Astorino 2026 | contextual other | Tanito 2025 (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Luevano-Contreras 2010 | contextual other | Tanito 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Nowotny 2015 | contextual other | Tanito 2025 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Chuntakaruk 2021 | contextual other | Tanito 2025 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Tanito 2025 | Steenbeke 2022 | contextual other | Tanito 2025 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Mishra 2025 | contextual other | Wellens 2025 (null) vs Mishra 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Li 2025b | contextual other | Wellens 2025 (null) vs Li 2025b (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Salmen 2025 | contextual other | Wellens 2025 (null) vs Salmen 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Kataoka 2025 | contextual other | Wellens 2025 (null) vs Kataoka 2025 (null) on contextual other | agreement (minor) |\n| null vs positive | 3 | Wellens 2025 | Varoniukaite 2025 | contextual other | Wellens 2025 (null) vs Varoniukaite 2025 (negative) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Wellens 2025 | Alharbi 2026 | contextual other | Wellens 2025 (null) vs Alharbi 2026 (negative) on contextual other | null vs positive (notable) |\n| agreement | 1 | Wellens 2025 | Selcuki 2026 | contextual other | Wellens 2025 (null) vs Selcuki 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Babtan 2026 | contextual other | Wellens 2025 (null) vs Babtan 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Astorino 2026 | contextual other | Wellens 2025 (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Luevano-Contreras 2010 | contextual other | Wellens 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Nowotny 2015 | contextual other | Wellens 2025 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Chuntakaruk 2021 | contextual other | Wellens 2025 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Wellens 2025 | Steenbeke 2022 | contextual other | Wellens 2025 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Mishra 2025 | Li 2025b | contextual other | Mishra 2025 (null) vs Li 2025b (null) on contextual other | agreement (minor) |\n| agreement | 1 | Mishra 2025 | Salmen 2025 | contextual other | Mishra 2025 (null) vs Salmen 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Mishra 2025 | Kataoka 2025 | contextual other | Mishra 2025 (null) vs Kataoka 2025 (null) on contextual other | agreement (minor) |\n| null vs positive | 3 | Mishra 2025 | Varoniukaite 2025 | contextual other | Mishra 2025 (null) vs Varoniukaite 2025 (negative) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Mishra 2025 | Alharbi 2026 | contextual other | Mishra 2025 (null) vs Alharbi 2026 (negative) on contextual other | null vs positive (notable) |\n| agreement | 1 | Mishra 2025 | Selcuki 2026 | contextual other | Mishra 2025 (null) vs Selcuki 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Mishra 2025 | Babtan 2026 | contextual other | Mishra 2025 (null) vs Babtan 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Mishra 2025 | Astorino 2026 | contextual other | Mishra 2025 (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Mishra 2025 | Luevano-Contreras 2010 | contextual other | Mishra 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Mishra 2025 | Nowotny 2015 | contextual other | Mishra 2025 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Mishra 2025 | Chuntakaruk 2021 | contextual other | Mishra 2025 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Mishra 2025 | Steenbeke 2022 | contextual other | Mishra 2025 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Li 2025b | Salmen 2025 | contextual other | Li 2025b (null) vs Salmen 2025 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Li 2025b | Kataoka 2025 | contextual other | Li 2025b (null) vs Kataoka 2025 (null) on contextual other | agreement (minor) |\n| null vs positive | 3 | Li 2025b | Varoniukaite 2025 | contextual other | Li 2025b (null) vs Varoniukaite 2025 (negative) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Li 2025b | Alharbi 2026 | contextual other | Li 2025b (null) vs Alharbi 2026 (negative) on contextual other | null vs positive (notable) |\n| agreement | 1 | Li 2025b | Selcuki 2026 | contextual other | Li 2025b (null) vs Selcuki 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Li 2025b | Babtan 2026 | contextual other | Li 2025b (null) vs Babtan 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Li 2025b | Astorino 2026 | contextual other | Li 2025b (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Li 2025b | Luevano-Contreras 2010 | contextual other | Li 2025b (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Li 2025b | Nowotny 2015 | contextual other | Li 2025b (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Li 2025b | Chuntakaruk 2021 | contextual other | Li 2025b (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Li 2025b | Steenbeke 2022 | contextual other | Li 2025b (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Salmen 2025 | Kataoka 2025 | contextual other | Salmen 2025 (null) vs Kataoka 2025 (null) on contextual other | agreement (minor) |\n| null vs positive | 3 | Salmen 2025 | Varoniukaite 2025 | contextual other | Salmen 2025 (null) vs Varoniukaite 2025 (negative) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Salmen 2025 | Alharbi 2026 | contextual other | Salmen 2025 (null) vs Alharbi 2026 (negative) on contextual other | null vs positive (notable) |\n| agreement | 1 | Salmen 2025 | Selcuki 2026 | contextual other | Salmen 2025 (null) vs Selcuki 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Salmen 2025 | Babtan 2026 | contextual other | Salmen 2025 (null) vs Babtan 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Salmen 2025 | Astorino 2026 | contextual other | Salmen 2025 (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Salmen 2025 | Luevano-Contreras 2010 | contextual other | Salmen 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Salmen 2025 | Nowotny 2015 | contextual other | Salmen 2025 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Salmen 2025 | Chuntakaruk 2021 | contextual other | Salmen 2025 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Salmen 2025 | Steenbeke 2022 | contextual other | Salmen 2025 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Melamed 2025 | Yurt 2025 | deficiency prevalence | Melamed 2025 (null) vs Yurt 2025 (null) on deficiency prevalence | agreement (minor) |\n| agreement | 1 | Melamed 2025 | Dahlen 2025 | deficiency prevalence | Melamed 2025 (null) vs Dahlen 2025 (null) on deficiency prevalence | agreement (minor) |\n| agreement | 1 | Yurt 2025 | Dahlen 2025 | deficiency prevalence | Yurt 2025 (null) vs Dahlen 2025 (null) on deficiency prevalence | agreement (minor) |\n| null vs positive | 3 | Li 2025 | Nevarez 2025 | cardiometabolic | Li 2025 (negative) vs Nevarez 2025 (null) on cardiometabolic | null vs positive (notable) |\n| null vs positive | 3 | Li 2025 | Movahedian 2025 | cardiometabolic | Li 2025 (negative) vs Movahedian 2025 (null) on cardiometabolic | null vs positive (notable) |\n| agreement | 1 | Nevarez 2025 | Movahedian 2025 | cardiometabolic | Nevarez 2025 (null) vs Movahedian 2025 (null) on cardiometabolic | agreement (minor) |\n| null vs positive | 3 | Kataoka 2025 | Varoniukaite 2025 | contextual other | Kataoka 2025 (null) vs Varoniukaite 2025 (negative) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Kataoka 2025 | Alharbi 2026 | contextual other | Kataoka 2025 (null) vs Alharbi 2026 (negative) on contextual other | null vs positive (notable) |\n| agreement | 1 | Kataoka 2025 | Selcuki 2026 | contextual other | Kataoka 2025 (null) vs Selcuki 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Kataoka 2025 | Babtan 2026 | contextual other | Kataoka 2025 (null) vs Babtan 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Kataoka 2025 | Astorino 2026 | contextual other | Kataoka 2025 (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Kataoka 2025 | Luevano-Contreras 2010 | contextual other | Kataoka 2025 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Kataoka 2025 | Nowotny 2015 | contextual other | Kataoka 2025 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Kataoka 2025 | Chuntakaruk 2021 | contextual other | Kataoka 2025 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Kataoka 2025 | Steenbeke 2022 | contextual other | Kataoka 2025 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Varoniukaite 2025 | Alharbi 2026 | contextual other | Varoniukaite 2025 (negative) vs Alharbi 2026 (negative) on contextual other | agreement (minor) |\n| null vs positive | 3 | Varoniukaite 2025 | Selcuki 2026 | contextual other | Varoniukaite 2025 (negative) vs Selcuki 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Varoniukaite 2025 | Babtan 2026 | contextual other | Varoniukaite 2025 (negative) vs Babtan 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Varoniukaite 2025 | Astorino 2026 | contextual other | Varoniukaite 2025 (negative) vs Astorino 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Varoniukaite 2025 | Luevano-Contreras 2010 | contextual other | Varoniukaite 2025 (negative) vs Luevano-Contreras 2010 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Varoniukaite 2025 | Nowotny 2015 | contextual other | Varoniukaite 2025 (negative) vs Nowotny 2015 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Varoniukaite 2025 | Chuntakaruk 2021 | contextual other | Varoniukaite 2025 (negative) vs Chuntakaruk 2021 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Varoniukaite 2025 | Steenbeke 2022 | contextual other | Varoniukaite 2025 (negative) vs Steenbeke 2022 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Alharbi 2026 | Selcuki 2026 | contextual other | Alharbi 2026 (negative) vs Selcuki 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Alharbi 2026 | Babtan 2026 | contextual other | Alharbi 2026 (negative) vs Babtan 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Alharbi 2026 | Astorino 2026 | contextual other | Alharbi 2026 (negative) vs Astorino 2026 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Alharbi 2026 | Luevano-Contreras 2010 | contextual other | Alharbi 2026 (negative) vs Luevano-Contreras 2010 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Alharbi 2026 | Nowotny 2015 | contextual other | Alharbi 2026 (negative) vs Nowotny 2015 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Alharbi 2026 | Chuntakaruk 2021 | contextual other | Alharbi 2026 (negative) vs Chuntakaruk 2021 (null) on contextual other | null vs positive (notable) |\n| null vs positive | 3 | Alharbi 2026 | Steenbeke 2022 | contextual other | Alharbi 2026 (negative) vs Steenbeke 2022 (null) on contextual other | null vs positive (notable) |\n| agreement | 1 | Selcuki 2026 | Babtan 2026 | contextual other | Selcuki 2026 (null) vs Babtan 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Selcuki 2026 | Astorino 2026 | contextual other | Selcuki 2026 (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Selcuki 2026 | Luevano-Contreras 2010 | contextual other | Selcuki 2026 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Selcuki 2026 | Nowotny 2015 | contextual other | Selcuki 2026 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Selcuki 2026 | Chuntakaruk 2021 | contextual other | Selcuki 2026 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Selcuki 2026 | Steenbeke 2022 | contextual other | Selcuki 2026 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Babtan 2026 | Astorino 2026 | contextual other | Babtan 2026 (null) vs Astorino 2026 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Babtan 2026 | Luevano-Contreras 2010 | contextual other | Babtan 2026 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Babtan 2026 | Nowotny 2015 | contextual other | Babtan 2026 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Babtan 2026 | Chuntakaruk 2021 | contextual other | Babtan 2026 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Babtan 2026 | Steenbeke 2022 | contextual other | Babtan 2026 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Astorino 2026 | Luevano-Contreras 2010 | contextual other | Astorino 2026 (null) vs Luevano-Contreras 2010 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Astorino 2026 | Nowotny 2015 | contextual other | Astorino 2026 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Astorino 2026 | Chuntakaruk 2021 | contextual other | Astorino 2026 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Astorino 2026 | Steenbeke 2022 | contextual other | Astorino 2026 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Luevano-Contreras 2010 | Nowotny 2015 | contextual other | Luevano-Contreras 2010 (null) vs Nowotny 2015 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Luevano-Contreras 2010 | Chuntakaruk 2021 | contextual other | Luevano-Contreras 2010 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Luevano-Contreras 2010 | Steenbeke 2022 | contextual other | Luevano-Contreras 2010 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Nowotny 2015 | Chuntakaruk 2021 | contextual other | Nowotny 2015 (null) vs Chuntakaruk 2021 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Nowotny 2015 | Steenbeke 2022 | contextual other | Nowotny 2015 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n| agreement | 1 | Chuntakaruk 2021 | Steenbeke 2022 | contextual other | Chuntakaruk 2021 (null) vs Steenbeke 2022 (null) on contextual other | agreement (minor) |\n\n### Table 4 (supplemental): Design-Level Evidence Weighting Heuristic\n\n*Per-domain grades are derived from each study's evidence tier (A1/A2/B1/B2/C1/C2) — they capture design-level limitations, NOT a formal per-paper risk-of-bias assessment from the source text. Domains follow design-family categories for randomized, observational, animal, and systematic-review evidence; `n/a` indicates the domain is not meaningful for that design (e.g. blinding for an observational cohort). The **Weight in synthesis** column is the qualitative weighting the synthesis applies to each source — derived from tier × directness × overall RoB.*\n\n| Citation | Tier | Tool | Allocation | Blinding | Attrition | Outcome measurement | Reporting | Confounding control | Generalizability | Overall RoB | Weight in synthesis | Effect direction notes |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Movahedian 2025 | A1 | Cochrane RoB-2 | low | low | moderate | low | low | low | moderate | low | **load-bearing** (direct clinical RCT) | primary endpoint did not reach significance |\n| Kopytek 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | negative effect — see Tables 1/2 |\n| Kabthymer 2024 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Li 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | negative effect — see Tables 1/2 |\n| Dahlen 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Ozdemir 2025 | A1 | Cochrane RoB-2 | low | low | moderate | low | low | low | moderate | low | **load-bearing** (direct clinical RCT) | negative effect — see Tables 1/2 |\n| Melamed 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Yurt 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Hauser 2024 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | negative effect — see Tables 1/2 |\n| Wellens 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Varoniukaite 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | negative effect — see Tables 1/2 |\n| Selcuki 2026 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Alharbi 2026 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | negative effect — see Tables 1/2 |\n| Steenbeke 2022 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Singh 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Xue 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Astorino 2026 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Takagi 2026 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Tanito 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Razak 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Park 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | positive effect — see Tables 1/2 |\n| Mishra 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Ursic 2026 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | positive effect — see Tables 1/2 |\n| Li 2025b | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Sukon 2024 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | positive effect — see Tables 1/2 |\n| Detopoulou 2024 | B1 | AMSTAR-2 (review) | unclear | unclear | unclear | unclear | moderate | moderate | moderate | unclear | **supporting** (synthesis evidence) | signed claims without significance signal |\n| Nevarez 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Zhao 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Pascual-Morena 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | signed claims without significance signal |\n| Kataoka 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| OToole 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Zhang 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Salmen 2025 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Lee 2026 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Babtan 2026 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Chuntakaruk 2021 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Nowotny 2015 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n| Luevano-Contreras 2010 | B2 | ROBINS-I | n/a | n/a | moderate | moderate | moderate | high | moderate | moderate | **contextual** (observational signal) | primary endpoint did not reach significance |\n\n### Table 5 (supplemental): Per-Paper Numeric Index\n\n*Top-N quantitative claims per paper — the underlying corpus numerics that power Q2 trace and Q9 density. One row per (paper × claim) tuple, prioritised by claim type (p-value > percentage > ratio > unit-value).*\n\n| Citation | Section | Type | Value | Units |\n| --- | --- | --- | --- | --- |\n| Movahedian 2025 | results | p-value | P = 0.04 | — |\n| Movahedian 2025 | results | p-value | P = 0.03 | — |\n| Ozdemir 2025 | abstract | p-value | P = 0.027 | — |\n| Ozdemir 2025 | discussion | unit value | 2 months | months |\n| Ozdemir 2025 | results | p-value | P < 0.005 | — |\n| Varoniukaite 2025 | results | p-value | P = 0.206 | — |\n| Varoniukaite 2025 | results | p-value | P = 0.005 | — |\n| Varoniukaite 2025 | results | p-value | P = 0.310 | — |\n| Alharbi 2026 | results | p-value | P < 0.001 | — |\n| Alharbi 2026 | results | odds ratio | OR: 2.16 | — |\n| Alharbi 2026 | results | confidence interval | 95% CI: 1.06-4.09 | 95%CI |\n| Ursic 2026 | discussion | unit value | 250 mg | mg |\n| Ursic 2026 | discussion | unit value | 16 weeks | weeks |\n| Ursic 2026 | discussion | unit value | 250 mg/kg/day | mg/kg/day |\n| Ursic 2026 | discussion | unit value | 1000 mg/kg/day | mg/kg/day |\n| Ursic 2026 | discussion | unit value | 1 month | month |\n| Detopoulou 2024 | discussion | percentage | 50% | % |\n\nAdditional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: ADA 2024, Cruz-Jentoft 2019.\n### References\n\n- **Movahedian 2025.** _Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-20792-2. PMID: 41125682.\n- **Kopytek 2025.** _Dysglycaemia is associated with the pattern of valvular calcification in micro-computed tomography analysis: an observational study in patients with severe aortic stenosis._ Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02691-y. PMID: 40114166.\n- **Kabthymer 2024.** _Carnosine/histidine-containing dipeptide supplementation improves depression and quality of life: systematic review and meta-analysis of randomized controlled trials._ Nutrition Reviews, 2024. DOI: 10.1093/nutrit/nuae021. PMID: 38545720.\n- **Li 2025.** _Effect of carnosine or beta-alanine supplementation therapy for prediabetes or type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials._ BMC Endocrine Disorders, 2025. DOI: 10.1186/s12902-025-02016-w. PMID: 40999397.\n- **Dahlen 2025.** _Fatigue and Vitamin D Status in Frail Elderly with and without Cancer, and Healthy Controls of Different Ages: Results from the IMAGE Study._ Gerontology, 2025. DOI: 10.1159/000548451. PMID: 40952957.\n- **Ozdemir 2025.** _Comparison of Metabolic and Hormonal Profiles between Low-Advanced Glycation End Products (AGEs) and Standard AGEs-Containing Weight-Loss Diets in Overweight Phenotype-A PCOS Patients: A Randomized Clinical Trial._ Reproductive Sciences, 2025. DOI: 10.1007/s43032-025-01808-8. PMID: 39953370.\n- **Melamed 2025.** _Prevalence, progression, and clinical outcomes of mitral valve prolapse: a systematic review and meta-analysis._ European Heart Journal. Quality of Care & Clinical Outcomes, 2025. DOI: 10.1093/ehjqcco/qcaf016. PMID: 40156585.\n- **Yurt 2025.** _Are Dietary and Serum Advanced Glycation End Products (AGEs) Potential Contributors to Inflammation in Women with Polycystic Ovary Syndrome?._ Journal of Clinical Medicine, 2025. DOI: 10.3390/jcm14165803. PMID: 40869631.\n- **Hauser 2024.** _Subcutaneous advanced glycation end products, cardiovascular risk factors and vascular health during childhood development in a Swiss population._ Frontiers in Physiology, 2024. DOI: 10.3389/fphys.2024.1371618. PMID: 39100277.\n- **Wellens 2025.** _Cooking methods affect advanced glycation end products and lipid profiles: A randomized cross-over study in healthy subjects._ Cell Reports Medicine, 2025. DOI: 10.1016/j.xcrm.2025.102091. PMID: 40280130.\n- **Varoniukaite 2025.** _Association of Advanced Glycation End Products with Diabetic Retinopathy Severity in Lithuanian Patients._ Medicina, 2025. DOI: 10.3390/medicina61111956. PMID: 41303793.\n- **Selcuki 2026.** _Systemic Oxidative Stress Markers in Endometriosis: Elevated Advanced Glycation End Products and Sestrin 2 in Women with Ovarian Endometrioma._ Biomedicines, 2026. DOI: 10.3390/biomedicines14020405.\n- **Alharbi 2026.** _Dietary advanced glycation end products (AGEs) and type 2 diabetes (T2D): a case-control study._ Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1737974. PMID: 41717025.\n- **Steenbeke 2022.** _Dietary Advanced Glycation End Products in an Elderly Population with Diabetic Nephropathy: An Exploratory Investigation._ Nutrients, 2022. DOI: 10.3390/nu14091818. PMID: 35565786.\n- **Singh 2025.** _Effectiveness of exercise for improving cognition, memory and executive function: a systematic umbrella review and meta-meta-analysis._ British Journal of Sports Medicine, 2025. DOI: 10.1136/bjsports-2024-108589. PMID: 40049759.\n- **Xue 2025.** _The relationship between advanced glycation end products, metabolic metrics, HbA 1c, and diabetic nephropathy._ Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2025.1468737. PMID: 40123890.\n- **Astorino 2026.** _The effect of low volume sprint interval training on cardiorespiratory fitness: study protocol for a definitive randomized controlled trial._ Trials, 2026. DOI: 10.1186/s13063-026-09647-x. PMID: 41872855.\n- **Takagi 2026.** _Association of Corneal Biomechanical Properties with Fingertip-Measured Advanced Glycation End Products and Carotenoids in Glaucoma Patients._ Journal of Clinical Medicine, 2026. DOI: 10.3390/jcm15020783. PMID: 41598720.\n- **Tanito 2025.** _Accelerated Biological Aging in Exfoliation Glaucoma Assessed by Fundus-Derived Predicted Age and Advanced Glycation End Products._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26104725. PMID: 40429867.\n- **Razak 2025.** _Effectiveness of Tocotrienol-Rich Fraction in Older Adults: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial._ JMIR Research Protocols, 2025. DOI: 10.2196/73039. PMID: 40986853.\n- **Park 2025.** _Advanced Glycation End Products and Mobility Decline: A Novel Perspective on Aging._ Healthcare, 2025. DOI: 10.3390/healthcare13060613. PMID: 40150465.\n- **Mishra 2025.** _Advanced glycation end products are biomolecular biomarkers for proliferative diabetic retinopathy._ Indian Journal of Ophthalmology, 2025. DOI: 10.4103/IJO.IJO_2115_24. PMID: 40243083.\n- **Ursic 2026.** _Carnosine-Enriched Chicken Meat Improves Microvascular Function and Anti-Inflammatory Phenotype in Patients with Chronic Coronary Syndrome._ Nutrients, 2026. DOI: 10.3390/nu18060928. PMID: 41901102.\n- **Li 2025b.** _The role of advanced glycation end products (AGEs) and the receptor for AGEs (RAGE) in hypertrophic obstructive cardiomyopathy._ PLOS One, 2025. DOI: 10.1371/journal.pone.0328032. PMID: 40705819.\n- **Sukon 2024.** _Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases._ International Ophthalmology, 2024. DOI: 10.1007/s10792-024-02980-7. PMID: 38329659.\n- **Detopoulou 2024.** _Dietary Restriction of Advanced Glycation End-Products (AGEs) in Patients with Diabetes: A Systematic Review of Randomized Controlled Trials._ International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms252111407. PMID: 39518960.\n- **Nevarez 2025.** _SAT-577 Assessing Advanced Glycation End-products (AGEs) in Type 1 Diabetes: Contributions of Serum, Dietary, and Skin AGEs._ Journal of the Endocrine Society, 2025. DOI: 10.1210/jendso/bvaf149.1108.\n- **Zhao 2025.** _Exploration of brain imaging biomarkers in subthreshold depression patients across different ages: an ALE meta-analysis based on MRI studies._ BMC Psychiatry, 2025. DOI: 10.1186/s12888-025-06495-y. PMID: 40033236.\n- **Pascual-Morena 2025.** _Association of Dietary Advanced Glycation End Products with Overall and Site-Specific Cancer Risk and Mortality: A Systematic Review and Meta-Analysis._ Nutrients, 2025. DOI: 10.3390/nu17101638. PMID: 40431378.\n- **Kataoka 2025.** _Current Developments in Analytical Methods for Advanced Glycation End Products in Foods._ Molecules, 2025. DOI: 10.3390/molecules30204095. PMID: 41157111.\n- **OToole 2025.** _Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial._ Neurotherapeutics, 2025. DOI: 10.1016/j.neurot.2025.e00541. PMID: 39919936.\n- **Zhang 2025.** _Advanced Glycation End Products in Disease Development and Potential Interventions._ Antioxidants, 2025. DOI: 10.3390/antiox14040492. PMID: 40298887.\n- **Salmen 2025.** _Could Skin Autofluorescence Be a Useful Biomarker in Systemic Lupus Erythematosus? A Systematic Review._ International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms26146934. PMID: 40725181.\n- **Lee 2026.** _Exploring the Anti-Inflammatory Effects of Aloe vera Flower (AVF) and Its Active Ingredients in a Skin Inflammation Model Induced by Glyoxal-Derived Advanced Glycation End Products (GO-AGEs)._ Pharmaceuticals, 2026. DOI: 10.3390/ph19010121. PMID: 41599719.\n- **Babtan 2026.** _Correlation Between Advanced Glycation End Products and Ultrasonographic Measurements of Cervico-Facial Skin Tissue._ Diagnostics, 2026. DOI: 10.3390/diagnostics16081206. PMID: 42072831.\n- **Chuntakaruk 2021.** _Chondroprotective effects of purple corn anthocyanins on advanced glycation end products induction through suppression of NF-κB and MAPK signaling._ Scientific Reports, 2021. DOI: 10.1038/s41598-021-81384-4. PMID: 33479339.\n- **Nowotny 2015.** _Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus._ Biomolecules, 2015. DOI: 10.3390/biom5010194. PMID: 25786107.\n- **Luevano-Contreras 2010.** _Dietary Advanced Glycation End Products and Aging._ Nutrients, 2010. DOI: 10.3390/nu2121247. PMID: 22254007.\n\n#### Background References\n\n*Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923. PMID: 21205966.\n- **Cesari 2009.** _Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779._ DOI: 10.1093/gerona/glp012. PMID: 19349594.\n- **Perera 2006.** _Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749._ DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.\n- **ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.\n- **Bohannon 1997.** _Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19._ DOI: 10.1093/ageing/26.1.15.\n- **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169. PMID: 30312372.\n- **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.\n","metadata":{"abstract":"This paper synthesizes carnosine anti glycation as an aging-related intervention across 38 included source papers and 1568 high-confidence extracted claims. The evidence profile contains 2 direct clinical sources, 26 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 205 cross-study disagreements across the evidence base. Positive study-level signals concentrate in the frailty, safety and comorbidity and immune and inflammation outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes, and negative signals in the contextual adjacent evidence and cardiometabolic outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that carnosine anti glycation remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.","article_type":"rapid_evidence_synthesis","counts":{"retrieved_count":38,"selected_count":38,"review_like_count":36,"primary_like_count":2,"year_start":2010,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":null,"identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/5N3MV","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"5n3mv","osf_url":"https://osf.io/5n3mv/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"5n3mv","url":"https://osf.io/5n3mv/","doi":"10.17605/OSF.IO/5N3MV"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"mimo-v2.5-pro|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"dw_artifact_id":"claim_3233e9a2f9ee463f","dw_chain_url":"https://provenance.researka.org/artifacts/claim_3233e9a2f9ee463f/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_3233e9a2f9ee463f/chain","dw_source_artifact_id":"source_5d614df452bb4017","dw_input_artifact_ids":["source_de84d6e3e5254ca9","source_bc02ffd7bd49429f","source_a4c8f32acc8e4da8","source_4d7c88fb70ee41d2","source_22117b92b2604df0","source_f1f3d0f90e474f3d"],"dw_step_id":"step_6309f7a950af4596","dw_step_hash":"13a7f98b076b447f210204dc46b5d8d01c457c0c3a25c2f0c240210dfcd315d8","dw_status":"registered","content_hash":"sha256:562d61ca23394d7b4f4255978454c70e5553604a3292466ec9cb7da2cd933e9f","sha256":"sha256:562d61ca23394d7b4f4255978454c70e5553604a3292466ec9cb7da2cd933e9f","osf_auth_source":"oauth_agent_token"},"created_at":"2026-05-31T22:13:12.161044+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"9f7abff5-de87-4959-b080-10eac9863ba7","traces":[{"claim_id":"claim_1","claim":"The evidence profile contains 2 direct clinical sources, 26 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 205 cross-study disagreements across the evidence base.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_2","claim":"Positive study-level signals concentrate in the frailty, safety and comorbidity and immune and inflammation outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes, and negative signals in the contextual adjacent evidence and cardiometabolic outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_3","claim":"The conclusion is that carnosine anti glycation remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_4","claim":"The global burden of age-related chronic disease — spanning cardiometabolic disorders, cognitive decline, and functional disability — has intensified the search for interventions that target fundamental aging biology rather than individual organ systems. Geroscience posits that hallmarks such as protein crosslinking, oxidative stress, and chronic low-grade inflammation represent shared upstream drivers of multiple disease trajectories, and that modulating these pathways could compress morbidity in later life. Among candidate molecules, Carnosine anti glycation has drawn attention as a naturally occurring dipeptide with putative anti-glycation, antioxidant, and metal-chelating properties. Yet the question of whether Carnosine anti glycation supplementation can meaningfully alter healthspan or lifespan trajectories in humans remains unresolved. Evidence suggests that even well-studied aging biomarkers such as gait speed — where thresholds of 0.8 m/s (Studenski 2011) and 0.6 m/s (Cesari 2009) delineate mobility risk strata — show annual declines on the order of 0.05 m/s (Bohannon 1997), underscoring the incremental nature of functional deterioration and the challenge of detecting intervention effects over realistic trial durations.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_5","claim":"Several unresolved questions constrain the translational potential of Carnosine anti glycation. First, the duration of most trials — typically under 12 weeks — may be insufficient to detect effects on endpoints such as vascular stiffness, renal function, or cognitive trajectories that unfold over years or decades. Second, population specificity poses a challenge: carnosine supplementation showed benefits in younger cognitive cohorts (OToole 2025) but not uniformly across age groups, and the relevance of AGE-reduction strategies may differ between diabetic and non-diabetic populations. Third, the tension between positive findings in immune-inflammation outcomes (Sukon 2024) and null mechanistic signals (Lee 2026) illustrates the broader difficulty of translating cell-level anti-glycation effects to clinical inflammation endpoints. Whether Carnosine anti glycation can deliver meaningful benefit in aging populations will require trials that extend beyond surrogate markers (Ioannidis 2005) to functional and hard clinical endpoints.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_6","claim":"This synthesis addresses these gaps by systematically mapping the evidence for Carnosine anti glycation across outcome classes, distinguishing clinical from mechanistic findings, and explicitly weighting the tensions that pervade the literature. Across 38 curated reference papers, positive signals appear in frailty and safety-comorbidity domains, while negative or null findings dominate cardiometabolic and contextual-outcome classes, with cross-study disagreements identified across outcome pairings. The structured approach separates the question of mechanistic plausibility — which appears well-supported by in-vitro and observational data — from clinical efficacy, which remains uncertain and context-dependent. By organizing evidence according to outcome class, directness, and effect direction, rather than presenting an exhaustive inventory of individual studies, this synthesis aims to clarify where Carnosine anti glycation evidence converges, where it diverges, and what specific gaps future trials must address. The central question — whether Carnosine anti glycation represents a viable anti-aging intervention — cannot be answered by any single study; it requires the kind of cross-domain integration attempted here, bounded by the recognition that the mechanistic-to-clinical translation remains incomplete.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_7","claim":"The background evidence for carnosine anti glycation is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Movahedian 2025, Ozdemir 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_8","claim":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_9","claim":"Across the retained sources, positive signals cluster around the frailty, safety and comorbidity and immune and inflammation outcome classes; null signals around the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes; and negative or adverse signals around the contextual adjacent evidence and cardiometabolic outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_10","claim":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_11","claim":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct clinical signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_12","claim":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_13","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Source verification in the public bundle is limited to reference-level metadata; reported statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_14","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_15","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, cognitive, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, frailty, immune, immune and inflammation, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_16","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_17","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_18","claim":"| Contextual Adjacent Evidence | n=20; claims=657 | null signal in 15/20 sources | 16 indirect; 4 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_19","claim":"| Cardiometabolic | n=6; claims=513 | null signal in 4/6 sources | 2 direct; 2 indirect; 2 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_20","claim":"| Deficiency Prevalence | n=3; claims=178 | null signal in 3/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_21","claim":"| Cognitive | n=1; claims=48 | null signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_22","claim":"| Dosing and Pharmacokinetics | n=1; claims=7 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_23","claim":"| Immune | n=1; claims=35 | null signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_24","claim":"| Muscle Function | n=1; claims=37 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_25","claim":"Mechanistically, carnosine's anti-glycation properties may attenuate AGE accumulation and downstream oxidative stress pathways relevant to cardiometabolic health. The clinical RCT by Movahedian 2025 provides direct evidence that AGE modulation via melatonin affects inflammation and oxidative stress markers. Ozdemir 2025's RCT data suggest that reducing dietary AGE intake can improve metabolic and hormonal profiles in PCOS patients. Observational data from Xue 2025 and Nevarez 2025 provide cross-sectional associations but cannot establish causality regarding AGE-mediated cardiometabolic pathways.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_26","claim":"Within-corpus tensions emerge between studies reporting null or non-significant findings and those demonstrating significant cardiometabolic benefits. Ozdemir 2025 demonstrated significant metabolic improvements (P = 0.001) that contrast with the null findings from observational studies. These disagreements suggest that carnosine's cardiometabolic effects are context-dependent, with intervention type, population, and endpoint specificity moderating the observed effects.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_27","claim":"The corpus contains a single direct evidence source addressing cognitive outcomes in the context of anti-glycation interventions: a systematic umbrella review and meta-meta-analysis by Singh 2025. This review synthesized evidence across multiple domains, reporting that shorter intervention durations of 1 to 3 months and exergames (video games requiring physical movement) showed the largest effects on general cognition and memory. The study design was observational and review-level, with no enrolled clinical population specific to carnosine supplementation (Singh 2025).","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_28","claim":"This pattern of mixed significance underscores the context-dependent nature of cognitive outcomes: short-duration interventions and active gaming modalities appear efficacious, whereas other exercise forms or durations may not reach significance. The evidence does not directly evaluate carnosine's anti-glycation mechanisms in cognitive domains.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_29","claim":"Mechanistically, the anti-glycation properties of carnosine may relate to cognitive outcomes through protection against advanced glycation end-product (AGE) accumulation in neural tissue, a pathway implicated in neurodegeneration. However, the sole available review (Singh 2025) does not address this mechanistic pathway directly; instead, it evaluates physical activity and exergaming interventions that may share downstream neuroprotective effects such as enhanced cerebral blood flow and neurotrophic factor expression. Preclinical data from the broader carnosine literature suggest glycation-inhibiting properties relevant to brain aging, but this mechanistic substrate is not yet grounded in human-RCT evidence specific to carnosine supplementation for cognition.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]},{"claim_id":"claim_30","claim":"Within the corpus, a notable tension exists: the cognitive outcome class is populated solely by Singh 2025, which addresses exercise rather than carnosine directly, creating an indirect evidence gap. This heterogeneity parallels the broader thesis that the carnosine anti-aging case remains incomplete: mechanistic plausibility for anti-glycation benefits in cognition coexists with sparse or absent direct human-RCT evidence for carnosine supplementation. The boundary conditions for any cognitive benefit remain to be established through targeted interventional trials.","candidate_sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w"},{"study":"Dahlen 2025","doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"9f7abff5-de87-4959-b080-10eac9863ba7","content_hash":"sha256:562d61ca23394d7b4f4255978454c70e5553604a3292466ec9cb7da2cd933e9f","nodes":[{"id":"9f7abff5-de87-4959-b080-10eac9863ba7","type":"publication","title":"Research Synthesis: Carnosine Anti-Glycation — full paper"},{"id":"claim_1","type":"claim","text":"The evidence profile contains 2 direct clinical sources, 26 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 205 cross-study disagreements across the evidence base."},{"id":"claim_2","type":"claim","text":"Positive study-level signals concentrate in the frailty, safety and comorbidity and immune and inflammation outcome classes, null signals in the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes, and negative signals in the contextual adjacent evidence and cardiometabolic outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect."},{"id":"claim_3","type":"claim","text":"The conclusion is that carnosine anti glycation remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim."},{"id":"claim_4","type":"claim","text":"The global burden of age-related chronic disease — spanning cardiometabolic disorders, cognitive decline, and functional disability — has intensified the search for interventions that target fundamental aging biology rather than individual organ systems. Geroscience posits that hallmarks such as protein crosslinking, oxidative stress, and chronic low-grade inflammation represent shared upstream drivers of multiple disease trajectories, and that modulating these pathways could compress morbidity in later life. Among candidate molecules, Carnosine anti glycation has drawn attention as a naturally occurring dipeptide with putative anti-glycation, antioxidant, and metal-chelating properties. Yet the question of whether Carnosine anti glycation supplementation can meaningfully alter healthspan or lifespan trajectories in humans remains unresolved. Evidence suggests that even well-studied aging biomarkers such as gait speed — where thresholds of 0.8 m/s (Studenski 2011) and 0.6 m/s (Cesari 2009) delineate mobility risk strata — show annual declines on the order of 0.05 m/s (Bohannon 1997), underscoring the incremental nature of functional deterioration and the challenge of detecting intervention effects over realistic trial durations."},{"id":"claim_5","type":"claim","text":"Several unresolved questions constrain the translational potential of Carnosine anti glycation. First, the duration of most trials — typically under 12 weeks — may be insufficient to detect effects on endpoints such as vascular stiffness, renal function, or cognitive trajectories that unfold over years or decades. Second, population specificity poses a challenge: carnosine supplementation showed benefits in younger cognitive cohorts (OToole 2025) but not uniformly across age groups, and the relevance of AGE-reduction strategies may differ between diabetic and non-diabetic populations. Third, the tension between positive findings in immune-inflammation outcomes (Sukon 2024) and null mechanistic signals (Lee 2026) illustrates the broader difficulty of translating cell-level anti-glycation effects to clinical inflammation endpoints. Whether Carnosine anti glycation can deliver meaningful benefit in aging populations will require trials that extend beyond surrogate markers (Ioannidis 2005) to functional and hard clinical endpoints."},{"id":"claim_6","type":"claim","text":"This synthesis addresses these gaps by systematically mapping the evidence for Carnosine anti glycation across outcome classes, distinguishing clinical from mechanistic findings, and explicitly weighting the tensions that pervade the literature. Across 38 curated reference papers, positive signals appear in frailty and safety-comorbidity domains, while negative or null findings dominate cardiometabolic and contextual-outcome classes, with cross-study disagreements identified across outcome pairings. The structured approach separates the question of mechanistic plausibility — which appears well-supported by in-vitro and observational data — from clinical efficacy, which remains uncertain and context-dependent. By organizing evidence according to outcome class, directness, and effect direction, rather than presenting an exhaustive inventory of individual studies, this synthesis aims to clarify where Carnosine anti glycation evidence converges, where it diverges, and what specific gaps future trials must address. The central question — whether Carnosine anti glycation represents a viable anti-aging intervention — cannot be answered by any single study; it requires the kind of cross-domain integration attempted here, bounded by the recognition that the mechanistic-to-clinical translation remains incomplete."},{"id":"claim_7","type":"claim","text":"The background evidence for carnosine anti glycation is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Movahedian 2025, Ozdemir 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation."},{"id":"claim_8","type":"claim","text":"The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect."},{"id":"claim_9","type":"claim","text":"Across the retained sources, positive signals cluster around the frailty, safety and comorbidity and immune and inflammation outcome classes; null signals around the contextual adjacent evidence, cardiometabolic and deficiency prevalence outcome classes; and negative or adverse signals around the contextual adjacent evidence and cardiometabolic outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation."},{"id":"claim_10","type":"claim","text":"The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty."},{"id":"claim_11","type":"claim","text":"The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct clinical signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support."},{"id":"claim_12","type":"claim","text":"This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance."},{"id":"claim_13","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Source verification in the public bundle is limited to reference-level metadata; reported statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_14","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_15","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, cognitive, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, frailty, immune, immune and inflammation, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_16","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_17","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence."},{"id":"claim_18","type":"claim","text":"| Contextual Adjacent Evidence | n=20; claims=657 | null signal in 15/20 sources | 16 indirect; 4 review | limited corpus depth in this outcome class |"},{"id":"claim_19","type":"claim","text":"| Cardiometabolic | n=6; claims=513 | null signal in 4/6 sources | 2 direct; 2 indirect; 2 review | limited corpus depth in this outcome class |"},{"id":"claim_20","type":"claim","text":"| Deficiency Prevalence | n=3; claims=178 | null signal in 3/3 sources | 2 indirect; 1 review | limited corpus depth in this outcome class |"},{"id":"claim_21","type":"claim","text":"| Cognitive | n=1; claims=48 | null signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |"},{"id":"claim_22","type":"claim","text":"| Dosing and Pharmacokinetics | n=1; claims=7 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |"},{"id":"claim_23","type":"claim","text":"| Immune | n=1; claims=35 | null signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating |"},{"id":"claim_24","type":"claim","text":"| Muscle Function | n=1; claims=37 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |"},{"id":"claim_25","type":"claim","text":"Mechanistically, carnosine's anti-glycation properties may attenuate AGE accumulation and downstream oxidative stress pathways relevant to cardiometabolic health. The clinical RCT by Movahedian 2025 provides direct evidence that AGE modulation via melatonin affects inflammation and oxidative stress markers. Ozdemir 2025's RCT data suggest that reducing dietary AGE intake can improve metabolic and hormonal profiles in PCOS patients. Observational data from Xue 2025 and Nevarez 2025 provide cross-sectional associations but cannot establish causality regarding AGE-mediated cardiometabolic pathways."},{"id":"claim_26","type":"claim","text":"Within-corpus tensions emerge between studies reporting null or non-significant findings and those demonstrating significant cardiometabolic benefits. Ozdemir 2025 demonstrated significant metabolic improvements (P = 0.001) that contrast with the null findings from observational studies. These disagreements suggest that carnosine's cardiometabolic effects are context-dependent, with intervention type, population, and endpoint specificity moderating the observed effects."},{"id":"claim_27","type":"claim","text":"The corpus contains a single direct evidence source addressing cognitive outcomes in the context of anti-glycation interventions: a systematic umbrella review and meta-meta-analysis by Singh 2025. This review synthesized evidence across multiple domains, reporting that shorter intervention durations of 1 to 3 months and exergames (video games requiring physical movement) showed the largest effects on general cognition and memory. The study design was observational and review-level, with no enrolled clinical population specific to carnosine supplementation (Singh 2025)."},{"id":"claim_28","type":"claim","text":"This pattern of mixed significance underscores the context-dependent nature of cognitive outcomes: short-duration interventions and active gaming modalities appear efficacious, whereas other exercise forms or durations may not reach significance. The evidence does not directly evaluate carnosine's anti-glycation mechanisms in cognitive domains."},{"id":"claim_29","type":"claim","text":"Mechanistically, the anti-glycation properties of carnosine may relate to cognitive outcomes through protection against advanced glycation end-product (AGE) accumulation in neural tissue, a pathway implicated in neurodegeneration. However, the sole available review (Singh 2025) does not address this mechanistic pathway directly; instead, it evaluates physical activity and exergaming interventions that may share downstream neuroprotective effects such as enhanced cerebral blood flow and neurotrophic factor expression. Preclinical data from the broader carnosine literature suggest glycation-inhibiting properties relevant to brain aging, but this mechanistic substrate is not yet grounded in human-RCT evidence specific to carnosine supplementation for cognition."},{"id":"claim_30","type":"claim","text":"Within the corpus, a notable tension exists: the cognitive outcome class is populated solely by Singh 2025, which addresses exercise rather than carnosine directly, creating an indirect evidence gap. This heterogeneity parallels the broader thesis that the carnosine anti-aging case remains incomplete: mechanistic plausibility for anti-glycation benefits in cognition coexists with sparse or absent direct human-RCT evidence for carnosine supplementation. The boundary conditions for any cognitive benefit remain to be established through targeted interventional trials."},{"id":"source_1","type":"source","study":"Movahedian 2025","year":2025,"doi":"10.1038/s41598-025-20792-2","url":"https://doi.org/10.1038/s41598-025-20792-2","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Kopytek 2025","year":2025,"doi":"10.1186/s12933-025-02691-y","url":"https://doi.org/10.1186/s12933-025-02691-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Kabthymer 2024","year":2024,"doi":"10.1093/nutrit/nuae021","url":"https://doi.org/10.1093/nutrit/nuae021","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_4","type":"source","study":"Li 2025","year":2025,"doi":"10.1186/s12902-025-02016-w","url":"https://doi.org/10.1186/s12902-025-02016-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_5","type":"source","study":"Dahlen 2025","year":2025,"doi":"10.1159/000548451","url":"https://doi.org/10.1159/000548451","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_6","type":"source","study":"Ozdemir 2025","year":2025,"doi":"10.1007/s43032-025-01808-8","url":"https://doi.org/10.1007/s43032-025-01808-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_7","type":"source","study":"Melamed 2025","year":2025,"doi":"10.1093/ehjqcco/qcaf016","url":"https://doi.org/10.1093/ehjqcco/qcaf016","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_8","type":"source","study":"Yurt 2025","year":2025,"doi":"10.3390/jcm14165803","url":"https://doi.org/10.3390/jcm14165803","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_9","type":"source","study":"Hauser 2024","year":2024,"doi":"10.3389/fphys.2024.1371618","url":"https://doi.org/10.3389/fphys.2024.1371618","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_10","type":"source","study":"Selcuki 2026","year":2026,"doi":"10.3390/biomedicines14020405","url":"https://doi.org/10.3390/biomedicines14020405","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_11","type":"source","study":"Wellens 2025","year":2025,"doi":"10.1016/j.xcrm.2025.102091","url":"https://doi.org/10.1016/j.xcrm.2025.102091","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_12","type":"source","study":"Varoniukaite 2025","year":2025,"doi":"10.3390/medicina61111956","url":"https://doi.org/10.3390/medicina61111956","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_13","type":"source","study":"Alharbi 2026","year":2026,"doi":"10.3389/fnut.2026.1737974","url":"https://doi.org/10.3389/fnut.2026.1737974","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_14","type":"source","study":"Steenbeke 2022","year":2022,"doi":"10.3390/nu14091818","url":"https://doi.org/10.3390/nu14091818","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_15","type":"source","study":"Singh 2025","year":2025,"doi":"10.1136/bjsports-2024-108589","url":"https://doi.org/10.1136/bjsports-2024-108589","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_16","type":"source","study":"Xue 2025","year":2025,"doi":"10.3389/fendo.2025.1468737","url":"https://doi.org/10.3389/fendo.2025.1468737","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_17","type":"source","study":"Astorino 2026","year":2026,"doi":"10.1186/s13063-026-09647-x","url":"https://doi.org/10.1186/s13063-026-09647-x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_18","type":"source","study":"Takagi 2026","year":2026,"doi":"10.3390/jcm15020783","url":"https://doi.org/10.3390/jcm15020783","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_19","type":"source","study":"Tanito 2025","year":2025,"doi":"10.3390/ijms26104725","url":"https://doi.org/10.3390/ijms26104725","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_20","type":"source","study":"Razak 2025","year":2025,"doi":"10.2196/73039","url":"https://doi.org/10.2196/73039","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_21","type":"source","study":"Park 2025","year":2025,"doi":"10.3390/healthcare13060613","url":"https://doi.org/10.3390/healthcare13060613","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_22","type":"source","study":"Mishra 2025","year":2025,"doi":"10.4103/IJO.IJO_2115_24","url":"https://doi.org/10.4103/IJO.IJO_2115_24","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_23","type":"source","study":"Ursic 2026","year":2026,"doi":"10.3390/nu18060928","url":"https://doi.org/10.3390/nu18060928","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_24","type":"source","study":"Li 2025b","year":2025,"doi":"10.1371/journal.pone.0328032","url":"https://doi.org/10.1371/journal.pone.0328032","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_25","type":"source","study":"Sukon 2024","year":2024,"doi":"10.1007/s10792-024-02980-7","url":"https://doi.org/10.1007/s10792-024-02980-7","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_26","type":"source","study":"Nevarez 2025","year":2025,"doi":"10.1210/jendso/bvaf149.1108","url":"https://doi.org/10.1210/jendso/bvaf149.1108","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_27","type":"source","study":"Detopoulou 2024","year":2024,"doi":"10.3390/ijms252111407","url":"https://doi.org/10.3390/ijms252111407","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_28","type":"source","study":"Zhao 2025","year":2025,"doi":"10.1186/s12888-025-06495-y","url":"https://doi.org/10.1186/s12888-025-06495-y","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_29","type":"source","study":"Pascual-Morena 2025","year":2025,"doi":"10.3390/nu17101638","url":"https://doi.org/10.3390/nu17101638","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_30","type":"source","study":"Kataoka 2025","year":2025,"doi":"10.3390/molecules30204095","url":"https://doi.org/10.3390/molecules30204095","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_31","type":"source","study":"OToole 2025","year":2025,"doi":"10.1016/j.neurot.2025.e00541","url":"https://doi.org/10.1016/j.neurot.2025.e00541","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_32","type":"source","study":"Zhang 2025","year":2025,"doi":"10.3390/antiox14040492","url":"https://doi.org/10.3390/antiox14040492","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_33","type":"source","study":"Lee 2026","year":2026,"doi":"10.3390/ph19010121","url":"https://doi.org/10.3390/ph19010121","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_34","type":"source","study":"Babtan 2026","year":2026,"doi":"10.3390/diagnostics16081206","url":"https://doi.org/10.3390/diagnostics16081206","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_35","type":"source","study":"Salmen 2025","year":2025,"doi":"10.3390/ijms26146934","url":"https://doi.org/10.3390/ijms26146934","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_36","type":"source","study":"Chuntakaruk 2021","year":2021,"doi":"10.1038/s41598-021-81384-4","url":"https://doi.org/10.1038/s41598-021-81384-4","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_37","type":"source","study":"Nowotny 2015","year":2015,"doi":"10.3390/biom5010194","url":"https://doi.org/10.3390/biom5010194","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_38","type":"source","study":"Luevano-Contreras 2010","year":2010,"doi":"10.3390/nu2121247","url":"https://doi.org/10.3390/nu2121247","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_39","type":"source","study":"Studenski 2011","year":null,"doi":"10.1001/jama.2010.1923","url":"https://doi.org/10.1001/jama.2010.1923","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_40","type":"source","study":"Cesari 2009","year":null,"doi":"10.1093/gerona/glp012","url":"https://doi.org/10.1093/gerona/glp012","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_41","type":"source","study":"Perera 2006","year":null,"doi":"10.1111/j.1532-5415.2006.00701.x","url":"https://doi.org/10.1111/j.1532-5415.2006.00701.x","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_42","type":"source","study":"ADA 2024","year":null,"doi":"10.2337/dc24-S006","url":"https://doi.org/10.2337/dc24-S006","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_43","type":"source","study":"Bohannon 1997","year":null,"doi":"10.1093/ageing/26.1.15","url":"https://doi.org/10.1093/ageing/26.1.15","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_44","type":"source","study":"Cruz-Jentoft 2019","year":null,"doi":"10.1093/ageing/afy169","url":"https://doi.org/10.1093/ageing/afy169","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_45","type":"source","study":"Ioannidis 2005","year":null,"doi":"10.1371/journal.pmed.0020124","url":"https://doi.org/10.1371/journal.pmed.0020124","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_1","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_2","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_3","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_4","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_5","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_6","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_7","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_8","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_9","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_10","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_11","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_12","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_13","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_14","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_15","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_16","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_17","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_18","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_19","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_20","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_21","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_22","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_23","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_24","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_25","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_26","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_27","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_28","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_29","type":"contains_claim"},{"from":"9f7abff5-de87-4959-b080-10eac9863ba7","to":"claim_30","type":"contains_claim"}],"screening":{"identified":38,"screened":38,"excluded":0,"included":38,"included_or_retained":38,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"38 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"9f7abff5-de87-4959-b080-10eac9863ba7","screening":{"identified":38,"screened":38,"excluded":0,"included":38,"included_or_retained":38,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"38 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that carnosine anti glycation remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","The global burden of age-related chronic disease — spanning cardiometabolic disorders, cognitive decline, and functional disability — has intensified the search for interventions that target fundamental aging biology rather than individual organ systems. Geroscience posits that hallmarks such as protein crosslinking, oxidative stress, and chronic low-grade inflammation represent shared upstream drivers of multiple disease trajectories, and that modulating these pathways could compress morbidity in later life. Among candidate molecules, Carnosine anti glycation has drawn attention as a naturally occurring dipeptide with putative anti-glycation, antioxidant, and metal-chelating properties. Yet the question of whether Carnosine anti glycation supplementation can meaningfully alter healthspan or lifespan trajectories in humans remains unresolved. Evidence suggests that even well-studied aging biomarkers such as gait speed — where thresholds of 0.8 m/s (Studenski 2011) and 0.6 m/s (Cesari 2009) delineate mobility risk strata — show annual declines on the order of 0.05 m/s (Bohannon 1997), underscoring the incremental nature of functional deterioration and the challenge of detecting intervention effects over realistic trial durations.","Several unresolved questions constrain the translational potential of Carnosine anti glycation. First, the duration of most trials — typically under 12 weeks — may be insufficient to detect effects on endpoints such as vascular stiffness, renal function, or cognitive trajectories that unfold over years or decades. Second, population specificity poses a challenge: carnosine supplementation showed benefits in younger cognitive cohorts (OToole 2025) but not uniformly across age groups, and the relevance of AGE-reduction strategies may differ between diabetic and non-diabetic populations. Third, the tension between positive findings in immune-inflammation outcomes (Sukon 2024) and null mechanistic signals (Lee 2026) illustrates the broader difficulty of translating cell-level anti-glycation effects to clinical inflammation endpoints. Whether Carnosine anti glycation can deliver meaningful benefit in aging populations will require trials that extend beyond surrogate markers (Ioannidis 2005) to functional and hard clinical endpoints.","This synthesis addresses these gaps by systematically mapping the evidence for Carnosine anti glycation across outcome classes, distinguishing clinical from mechanistic findings, and explicitly weighting the tensions that pervade the literature. Across 38 curated reference papers, positive signals appear in frailty and safety-comorbidity domains, while negative or null findings dominate cardiometabolic and contextual-outcome classes, with cross-study disagreements identified across outcome pairings. The structured approach separates the question of mechanistic plausibility — which appears well-supported by in-vitro and observational data — from clinical efficacy, which remains uncertain and context-dependent. By organizing evidence according to outcome class, directness, and effect direction, rather than presenting an exhaustive inventory of individual studies, this synthesis aims to clarify where Carnosine anti glycation evidence converges, where it diverges, and what specific gaps future trials must address. The central question — whether Carnosine anti glycation represents a viable anti-aging intervention — cannot be answered by any single study; it requires the kind of cross-domain integration attempted here, bounded by the recognition that the mechanistic-to-clinical translation remains incomplete.","The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.","The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.","Mechanistically, carnosine's anti-glycation properties may attenuate AGE accumulation and downstream oxidative stress pathways relevant to cardiometabolic health. The clinical RCT by Movahedian 2025 provides direct evidence that AGE modulation via melatonin affects inflammation and oxidative stress markers. Ozdemir 2025's RCT data suggest that reducing dietary AGE intake can improve metabolic and hormonal profiles in PCOS patients. Observational data from Xue 2025 and Nevarez 2025 provide cross-sectional associations but cannot establish causality regarding AGE-mediated cardiometabolic pathways.","This pattern of mixed significance underscores the context-dependent nature of cognitive outcomes: short-duration interventions and active gaming modalities appear efficacious, whereas other exercise forms or durations may not reach significance. The evidence does not directly evaluate carnosine's anti-glycation mechanisms in cognitive domains.","Mechanistically, the anti-glycation properties of carnosine may relate to cognitive outcomes through protection against advanced glycation end-product (AGE) accumulation in neural tissue, a pathway implicated in neurodegeneration. However, the sole available review (Singh 2025) does not address this mechanistic pathway directly; instead, it evaluates physical activity and exergaming interventions that may share downstream neuroprotective effects such as enhanced cerebral blood flow and neurotrophic factor expression. Preclinical data from the broader carnosine literature suggest glycation-inhibiting properties relevant to brain aging, but this mechanistic substrate is not yet grounded in human-RCT evidence specific to carnosine supplementation for cognition.","Within the corpus, a notable tension exists: the cognitive outcome class is populated solely by Singh 2025, which addresses exercise rather than carnosine directly, creating an indirect evidence gap. This heterogeneity parallels the broader thesis that the carnosine anti-aging case remains incomplete: mechanistic plausibility for anti-glycation benefits in cognition coexists with sparse or absent direct human-RCT evidence for carnosine supplementation. The boundary conditions for any cognitive benefit remain to be established through targeted interventional trials."]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nMovahedian 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nKopytek 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nKabthymer 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLi 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nDahlen 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nOzdemir 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMelamed 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nYurt 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nHauser 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSelcuki 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nWellens 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nVaroniukaite 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nAlharbi 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSteenbeke 2022,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSingh 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nXue 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nAstorino 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nTakagi 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nTanito 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nRazak 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nPark 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nMishra 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nUrsic 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLi 2025b,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSukon 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nNevarez 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nDetopoulou 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nZhao 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nPascual-Morena 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nKataoka 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nOToole 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nZhang 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLee 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nBabtan 2026,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSalmen 2025,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nChuntakaruk 2021,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nNowotny 2015,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nLuevano-Contreras 2010,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nStudenski 2011,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\nCesari 2009,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\nPerera 2006,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\nADA 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\nBohannon 1997,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\nCruz-Jentoft 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\nIoannidis 2005,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"9f7abff5-de87-4959-b080-10eac9863ba7","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Movahedian 2025","doi":"10.1038/s41598-025-20792-2","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Kopytek 2025","doi":"10.1186/s12933-025-02691-y","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Kabthymer 2024","doi":"10.1093/nutrit/nuae021","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Li 2025","doi":"10.1186/s12902-025-02016-w","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Dahlen 2025","doi":"10.1159/000548451","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Ozdemir 2025","doi":"10.1007/s43032-025-01808-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Melamed 2025","doi":"10.1093/ehjqcco/qcaf016","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Yurt 2025","doi":"10.3390/jcm14165803","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Hauser 2024","doi":"10.3389/fphys.2024.1371618","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Selcuki 2026","doi":"10.3390/biomedicines14020405","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Wellens 2025","doi":"10.1016/j.xcrm.2025.102091","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Varoniukaite 2025","doi":"10.3390/medicina61111956","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Alharbi 2026","doi":"10.3389/fnut.2026.1737974","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Steenbeke 2022","doi":"10.3390/nu14091818","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Singh 2025","doi":"10.1136/bjsports-2024-108589","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Xue 2025","doi":"10.3389/fendo.2025.1468737","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Astorino 2026","doi":"10.1186/s13063-026-09647-x","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Takagi 2026","doi":"10.3390/jcm15020783","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Tanito 2025","doi":"10.3390/ijms26104725","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Razak 2025","doi":"10.2196/73039","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Park 2025","doi":"10.3390/healthcare13060613","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Mishra 2025","doi":"10.4103/IJO.IJO_2115_24","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Ursic 2026","doi":"10.3390/nu18060928","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Li 2025b","doi":"10.1371/journal.pone.0328032","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Sukon 2024","doi":"10.1007/s10792-024-02980-7","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Nevarez 2025","doi":"10.1210/jendso/bvaf149.1108","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Detopoulou 2024","doi":"10.3390/ijms252111407","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Zhao 2025","doi":"10.1186/s12888-025-06495-y","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Pascual-Morena 2025","doi":"10.3390/nu17101638","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Kataoka 2025","doi":"10.3390/molecules30204095","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"OToole 2025","doi":"10.1016/j.neurot.2025.e00541","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Zhang 2025","doi":"10.3390/antiox14040492","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Lee 2026","doi":"10.3390/ph19010121","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Babtan 2026","doi":"10.3390/diagnostics16081206","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Salmen 2025","doi":"10.3390/ijms26146934","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Chuntakaruk 2021","doi":"10.1038/s41598-021-81384-4","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Nowotny 2015","doi":"10.3390/biom5010194","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Luevano-Contreras 2010","doi":"10.3390/nu2121247","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Studenski 2011","doi":"10.1001/jama.2010.1923","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Cesari 2009","doi":"10.1093/gerona/glp012","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Perera 2006","doi":"10.1111/j.1532-5415.2006.00701.x","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"ADA 2024","doi":"10.2337/dc24-S006","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Bohannon 1997","doi":"10.1093/ageing/26.1.15","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Cruz-Jentoft 2019","doi":"10.1093/ageing/afy169","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Ioannidis 2005","doi":"10.1371/journal.pmed.0020124","risk_of_bias":"not appraised in public sidecar","directness":"citation"}]}}]}